<?xml version="1.0" encoding="UTF-8"?>
<CustomObjectTranslation xmlns="http://soap.sforce.com/2006/04/metadata">
    <caseValues>
        <caseType>Nominative</caseType>
        <plural>false</plural>
        <possessive>None</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Nominative</caseType>
        <plural>true</plural>
        <possessive>None</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Nominative</caseType>
        <plural>false</plural>
        <possessive>First</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Nominative</caseType>
        <plural>true</plural>
        <possessive>First</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Nominative</caseType>
        <plural>false</plural>
        <possessive>Second</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Nominative</caseType>
        <plural>true</plural>
        <possessive>Second</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Accusative</caseType>
        <plural>false</plural>
        <possessive>None</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Accusative</caseType>
        <plural>true</plural>
        <possessive>None</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Accusative</caseType>
        <plural>false</plural>
        <possessive>First</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Accusative</caseType>
        <plural>true</plural>
        <possessive>First</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Accusative</caseType>
        <plural>false</plural>
        <possessive>Second</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Accusative</caseType>
        <plural>true</plural>
        <possessive>Second</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Genitive</caseType>
        <plural>false</plural>
        <possessive>None</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Genitive</caseType>
        <plural>true</plural>
        <possessive>None</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Genitive</caseType>
        <plural>false</plural>
        <possessive>First</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Genitive</caseType>
        <plural>true</plural>
        <possessive>First</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Genitive</caseType>
        <plural>false</plural>
        <possessive>Second</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Genitive</caseType>
        <plural>true</plural>
        <possessive>Second</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Dative</caseType>
        <plural>false</plural>
        <possessive>None</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Dative</caseType>
        <plural>true</plural>
        <possessive>None</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Dative</caseType>
        <plural>false</plural>
        <possessive>First</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Dative</caseType>
        <plural>true</plural>
        <possessive>First</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Dative</caseType>
        <plural>false</plural>
        <possessive>Second</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Dative</caseType>
        <plural>true</plural>
        <possessive>Second</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Ablative</caseType>
        <plural>false</plural>
        <possessive>None</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Ablative</caseType>
        <plural>true</plural>
        <possessive>None</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Ablative</caseType>
        <plural>false</plural>
        <possessive>First</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Ablative</caseType>
        <plural>true</plural>
        <possessive>First</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Ablative</caseType>
        <plural>false</plural>
        <possessive>Second</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Ablative</caseType>
        <plural>true</plural>
        <possessive>Second</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Locative</caseType>
        <plural>false</plural>
        <possessive>None</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Locative</caseType>
        <plural>true</plural>
        <possessive>None</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Locative</caseType>
        <plural>false</plural>
        <possessive>First</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Locative</caseType>
        <plural>true</plural>
        <possessive>First</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <caseValues>
        <caseType>Locative</caseType>
        <plural>false</plural>
        <possessive>Second</possessive>
        <value>Ziyaret Müzakeresi</value>
    </caseValues>
    <caseValues>
        <caseType>Locative</caseType>
        <plural>true</plural>
        <possessive>Second</possessive>
        <value>Ziyaret Müzakereleri</value>
    </caseValues>
    <fields>
        <label><!-- Account_Source_Country_BMS_CORE --></label>
        <name>Account_Source_Country_BMS_CORE__c</name>
    </fields>
    <fields>
        <label>Hesap Taktiği</label>
        <name>Account_Tactic_vod__c</name>
        <relationshipLabel>Ziyaret Müzakereleri</relationshipLabel>
    </fields>
    <fields>
        <label>Hesap</label>
        <name>Account_vod__c</name>
        <relationshipLabel>Ziyaret Müzakereleri(Hesaplar)</relationshipLabel>
    </fields>
    <fields>
        <label><!-- Activity ID --></label>
        <name>Activity_ID_BMS__c</name>
    </fields>
    <fields>
        <label>Etkinlik</label>
        <name>Activity__c</name>
        <picklistValues>
            <masterLabel>Contracts Discussion</masterLabel>
            <translation>Kontrat Müzakeresi</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Dinner meeting</masterLabel>
            <translation>Akşam yemeği buluşması</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Email exchange</masterLabel>
            <translation>E-posta değişimi</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lunch meeting</masterLabel>
            <translation>Öğlen yemeği  buluşması</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Meeting</masterLabel>
            <translation>Buluşma</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation>Diğer</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Presentation</masterLabel>
            <translation>Sunum</translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Answer --></label>
        <name>Answer_BMS__c</name>
    </fields>
    <fields>
        <label>Katılımcı Türü</label>
        <name>Attendee_Type_vod__c</name>
        <picklistValues>
            <masterLabel>Contact_vod</masterLabel>
            <translation>İrtibat</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Event_vod</masterLabel>
            <translation>Olay</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Group_Account_vod</masterLabel>
            <translation>Grup Hesabı</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Person_Account_vod</masterLabel>
            <translation>Bireysel Hesap</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>User_vod</masterLabel>
            <translation>Kullanıcı</translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Barrier Reason --></label>
        <name>Barrier_Reason_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>Concern on  safety of high dosage of Glucophage</masterLabel>
            <translation><!-- Concern on  safety of high dosage of Glucophage --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Concern on  safety of long term usage of Glucophage</masterLabel>
            <translation><!-- Concern on  safety of long term usage of Glucophage --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DELETE</masterLabel>
            <translation><!-- DELETE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_1_1</masterLabel>
            <translation><!-- Eliquis_BR_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_1_2</masterLabel>
            <translation><!-- Eliquis_BR_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_1_3</masterLabel>
            <translation><!-- Eliquis_BR_1_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_2_1</masterLabel>
            <translation><!-- Eliquis_BR_1_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_2_2</masterLabel>
            <translation><!-- Eliquis_BR_1_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_3_1</masterLabel>
            <translation><!-- Eliquis_BR_1_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_3_2</masterLabel>
            <translation><!-- Eliquis_BR_1_3_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_3_3</masterLabel>
            <translation><!-- Eliquis_BR_1_3_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_4_1</masterLabel>
            <translation><!-- Eliquis_BR_1_4_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_BR_Achieved</masterLabel>
            <translation><!-- Glu_BR_Achieved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_1_1_1</masterLabel>
            <translation><!-- Monopril_BR_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_1_2_1</masterLabel>
            <translation><!-- Monopril_BR_1_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_1_2_2</masterLabel>
            <translation><!-- Monopril_BR_1_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_1_3_1</masterLabel>
            <translation><!-- Monopril_BR_1_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_1_3_2</masterLabel>
            <translation><!-- Monopril_BR_1_3_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_2_2_2</masterLabel>
            <translation><!-- Monopril_BR_2_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_2_2_3</masterLabel>
            <translation><!-- Monopril_BR_2_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_2_3_3</masterLabel>
            <translation><!-- Monopril_BR_2_3_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_3_2_2</masterLabel>
            <translation><!-- Monopril_BR_3_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_3_2_3</masterLabel>
            <translation><!-- Monopril_BR_3_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_4_3_1</masterLabel>
            <translation><!-- Monopril_BR_4_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_Achieved</masterLabel>
            <translation><!-- Monopril_BR_Achieved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>More earlier combination therapy instead of titrate to Metformin optimal dosage</masterLabel>
            <translation><!-- More earlier combination therapy instead of titrate to Metformin optimal dosage --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_BR_1_1_1</masterLabel>
            <translation><!-- Onglyza_BR_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_BR_1_1_2</masterLabel>
            <translation><!-- Onglyza_BR_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_BR_1_2_1</masterLabel>
            <translation><!-- Onglyza_BR_1_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_BR_1_2_2</masterLabel>
            <translation><!-- Onglyza_BR_1_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_BR_1_3_1</masterLabel>
            <translation><!-- Onglyza_BR_1_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_BR_1_3_2</masterLabel>
            <translation><!-- Onglyza_BR_1_3_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_BR_2_1_2</masterLabel>
            <translation><!-- Onglyza_BR_2_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_1_1_1</masterLabel>
            <translation><!-- Paraplatin_BR_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_1_1_2</masterLabel>
            <translation><!-- Paraplatin_BR_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_1_1_3</masterLabel>
            <translation><!-- Paraplatin_BR_1_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_1_1_4</masterLabel>
            <translation><!-- Paraplatin_BR_1_1_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_1_1_5</masterLabel>
            <translation><!-- Paraplatin_BR_1_1_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_1_1_6</masterLabel>
            <translation><!-- Paraplatin_BR_1_1_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_1_2_1</masterLabel>
            <translation><!-- Paraplatin_BR_1_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_2_1_1</masterLabel>
            <translation><!-- Paraplatin_BR_2_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_2_1_2</masterLabel>
            <translation><!-- Paraplatin_BR_2_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_2_2_1</masterLabel>
            <translation><!-- Paraplatin_BR_2_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_2_2_2</masterLabel>
            <translation><!-- Paraplatin_BR_2_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prescriber believe PPG control is the important attributes in Type 2 DM</masterLabel>
            <translation><!-- Prescriber believe PPG control is the important attributes in Type 2 DM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prescriber misunderstanding Glucophage side effect</masterLabel>
            <translation><!-- Prescriber misunderstanding Glucophage side effect --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_1_1_1</masterLabel>
            <translation><!-- Taxol_BR_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_1_1_2</masterLabel>
            <translation><!-- Taxol_BR_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_1_1_3</masterLabel>
            <translation><!-- Taxol_BR_1_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_1_1_4</masterLabel>
            <translation><!-- Taxol_BR_1_1_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_1_2_1</masterLabel>
            <translation><!-- Taxol_BR_1_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_1_3_1</masterLabel>
            <translation><!-- Taxol_BR_1_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_2_1_1</masterLabel>
            <translation><!-- Taxol_BR_2_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_2_1_2</masterLabel>
            <translation><!-- Taxol_BR_2_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_2_1_4</masterLabel>
            <translation><!-- Taxol_BR_2_1_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_2_1_5</masterLabel>
            <translation><!-- Taxol_BR_2_1_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_2_2_1</masterLabel>
            <translation><!-- Taxol_BR_2_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_2_2_2</masterLabel>
            <translation><!-- Taxol_BR_2_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_2_2_5</masterLabel>
            <translation><!-- Taxol_BR_2_2_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_2_3_1</masterLabel>
            <translation><!-- Taxol_BR_2_3_1 --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label>Çağrı mobil Kodu</label>
        <name>Call2_Mobile_ID_vod__c</name>
    </fields>
    <fields>
        <label>Ziyaret</label>
        <name>Call2_vod__c</name>
        <relationshipLabel>Ziyaret Müzakereleri</relationshipLabel>
    </fields>
    <fields>
        <label>Tarih</label>
        <name>Call_Date_vod__c</name>
    </fields>
    <fields>
        <label><!-- Clinical Trial --></label>
        <name>Clinical_Trial_BMS_EMEA__c</name>
        <picklistValues>
            <masterLabel>ACTION</masterLabel>
            <translation><!-- ACTION --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AEGEAN</masterLabel>
            <translation><!-- AEGEAN --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AEGEAN (Adherence)</masterLabel>
            <translation><!-- AEGEAN (Adherence) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AI424-402 study: HARNESS ATV+RAL</masterLabel>
            <translation><!-- AI424-402 study: HARNESS ATV+RAL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AI424-494 study: ATV/r + 3TC</masterLabel>
            <translation><!-- AI424-494 study: ATV/r + 3TC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AI438-011: Safety, efficacy, dose finding BMS-663068 in treatment exp.</masterLabel>
            <translation><!-- AI438-011: Safety, efficacy, dose finding BMS-663068 in treatment exp. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AI467-003: Safety, efficacy, dose finding BMS-986001 in treatment naïve</masterLabel>
            <translation><!-- AI467-003: Safety, efficacy, dose finding BMS-986001 in treatment naïve --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ALLURE</masterLabel>
            <translation><!-- ALLURE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AMPLIFY</masterLabel>
            <translation><!-- AMPLIFY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ANNEXA-A (Portola Ph 3)</masterLabel>
            <translation><!-- ANNEXA-A (Portola Ph 3) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>APPIPRA</masterLabel>
            <translation><!-- APPIPRA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ARCADIA</masterLabel>
            <translation><!-- ARCADIA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ARTESiA (Subclinical AF)</masterLabel>
            <translation><!-- ARTESiA (Subclinical AF) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ASCORE</masterLabel>
            <translation><!-- ASCORE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ASSET</masterLabel>
            <translation><!-- ASSET --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ASTREA</masterLabel>
            <translation><!-- ASTREA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ATLANTIS (TAVI)</masterLabel>
            <translation><!-- ATLANTIS (TAVI) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AUGUSTUS (Safety)</masterLabel>
            <translation><!-- AUGUSTUS (Safety) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVERT-2</masterLabel>
            <translation><!-- AVERT-2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AXAFA (Ablation)</masterLabel>
            <translation><!-- AXAFA (Ablation) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AZ 19 - safety and efficacy in CV risk pts (ST + LT)</masterLabel>
            <translation><!-- AZ 19 - safety and efficacy in CV risk pts (ST + LT) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AZ04/BMS 022 - add on to met failures</masterLabel>
            <translation><!-- AZ04/BMS 022 - add on to met failures --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AZ06/BMS 33 LTE - add on to insulin</masterLabel>
            <translation><!-- AZ06/BMS 33 LTE - add on to insulin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AZ10/BMS 61 - add on to DPP-IV (ST + LT)</masterLabel>
            <translation><!-- AZ10/BMS 61 - add on to DPP-IV (ST + LT) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AZ18/BMS 67 - safety and efficacy in CV risk pts (ST+LT)</masterLabel>
            <translation><!-- AZ18/BMS 67 - safety and efficacy in CV risk pts (ST+LT) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Adjuvant 029</masterLabel>
            <translation><!-- Adjuvant 029 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS 029 - Moderate RI</masterLabel>
            <translation><!-- BMS 029 - Moderate RI --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS 073 - Blood pressure</masterLabel>
            <translation><!-- BMS 073 - Blood pressure --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS 077 - Follow on Blood pressure study</masterLabel>
            <translation><!-- BMS 077 - Follow on Blood pressure study --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 184-437 Ipi 3 vs. 10 in CRPC</masterLabel>
            <translation><!-- CA 184-437 Ipi 3 vs. 10 in CRPC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 186-011 Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin&apos;s Lymphoma</masterLabel>
            <translation><!-- CA 186-011 Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin&apos;s Lymphoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 186-017 Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma or CLL</masterLabel>
            <translation><!-- CA 186-017 Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma or CLL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 204-004 ELOQUENT-2</masterLabel>
            <translation><!-- CA 204-004 ELOQUENT-2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 204-006 ELOQUENT-1</masterLabel>
            <translation><!-- CA 204-006 ELOQUENT-1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 209-205 Nivo in cl. Hodgkin Lymphoma</masterLabel>
            <translation><!-- CA 209-205 Nivo in cl. Hodgkin Lymphoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 209-214 Nivo in RCC</masterLabel>
            <translation><!-- CA 209-214 Nivo in RCC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 209-227 NSCLC</masterLabel>
            <translation><!-- CA 209-227 NSCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 209-238 Nivo vs. Ipi adjuvant melanoma</masterLabel>
            <translation><!-- CA 209-238 Nivo vs. Ipi adjuvant melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 209-275 Nivo in urothelial</masterLabel>
            <translation><!-- CA 209-275 Nivo in urothelial --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 209-331 SCLC</masterLabel>
            <translation><!-- CA 209-331 SCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA180-226 Pediatric</masterLabel>
            <translation><!-- CA180-226 Pediatric --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA180-330 SIMPLICITY</masterLabel>
            <translation><!-- CA180-330 SIMPLICITY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA180-399 DASCERN</masterLabel>
            <translation><!-- CA180-399 DASCERN --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA180-406 DASFREE</masterLabel>
            <translation><!-- CA180-406 DASFREE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA184-143 IMAGE</masterLabel>
            <translation><!-- CA184-143 IMAGE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA186-011 B-NH Lymphoma</masterLabel>
            <translation><!-- CA186-011 B-NH Lymphoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA204-008 PREAMBLE</masterLabel>
            <translation><!-- CA204-008 PREAMBLE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA204-125 ELOQUENT-3</masterLabel>
            <translation><!-- CA204-125 ELOQUENT-3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-026 1st Line Lung</masterLabel>
            <translation><!-- CA209-026 1st Line Lung --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-032 Solid Tumors</masterLabel>
            <translation><!-- CA209-032 Solid Tumors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-139 DLBC Lymphoma</masterLabel>
            <translation><!-- CA209-139 DLBC Lymphoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-140 Follicular Lymph</masterLabel>
            <translation><!-- CA209-140 Follicular Lymph --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-141 Head &amp; Neck</masterLabel>
            <translation><!-- CA209-141 Head &amp; Neck --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-142</masterLabel>
            <translation><!-- CA209-142 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-142 CRC</masterLabel>
            <translation><!-- CA209-142 CRC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-143 GBM</masterLabel>
            <translation><!-- CA209-143 GBM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-171 Lung</masterLabel>
            <translation><!-- CA209-171 Lung --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-172 Melanoma</masterLabel>
            <translation><!-- CA209-172 Melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-205 cHL-ASCT</masterLabel>
            <translation><!-- CA209-205 cHL-ASCT --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-214 RCC</masterLabel>
            <translation><!-- CA209-214 RCC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-227 NSCLC</masterLabel>
            <translation><!-- CA209-227 NSCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-234 RWD</masterLabel>
            <translation><!-- CA209-234 RWD --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-238 Adj Melanoma</masterLabel>
            <translation><!-- CA209-238 Adj Melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-274 Bladder / Urothelial</masterLabel>
            <translation><!-- CA209-274 Bladder / Urothelial --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-275 Urethral</masterLabel>
            <translation><!-- CA209-275 Urethral --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-331 SCLC</masterLabel>
            <translation><!-- CA209-331 SCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-357 OPTIMIzE</masterLabel>
            <translation><!-- CA209-357 OPTIMIzE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-370 SUSTAIN</masterLabel>
            <translation><!-- CA209-370 SUSTAIN --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-384 Dose freq. opt</masterLabel>
            <translation><!-- CA209-384 Dose freq. opt --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-401</masterLabel>
            <translation><!-- CA209-401 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-417 Lung</masterLabel>
            <translation><!-- CA209-417 Lung --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-436 NHL</masterLabel>
            <translation><!-- CA209-436 NHL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-451 SCLC</masterLabel>
            <translation><!-- CA209-451 SCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-459 HCC</masterLabel>
            <translation><!-- CA209-459 HCC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-511 Melanoma Dose Combi</masterLabel>
            <translation><!-- CA209-511 Melanoma Dose Combi --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-568 NSCLC</masterLabel>
            <translation><!-- CA209-568 NSCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-577 Oesophageal</masterLabel>
            <translation><!-- CA209-577 Oesophageal --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-744 cHL in children, adolescents &amp; young adults</masterLabel>
            <translation><!-- CA209-744 cHL in children, adolescents &amp; young adults --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN138-502</masterLabel>
            <translation><!-- CN138-502 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CRC-142</masterLabel>
            <translation><!-- CRC-142 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CV 185-316 Safety of Apixaban vs. VKA+Aspirin vs. Aspirin Placebo in Patients with AF and ACS or Percutaneous Coronary Intervention</masterLabel>
            <translation><!-- CV 185-316 Safety of Apixaban vs. VKA+Aspirin vs. Aspirin Placebo in Patients with AF and ACS or Percutaneous Coronary Intervention --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clazakizumab trials</masterLabel>
            <translation><!-- Clazakizumab trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DASCERN CA180-399</masterLabel>
            <translation><!-- DASCERN CA180-399 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DASFREE CA180-406</masterLabel>
            <translation><!-- DASFREE CA180-406 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DASPERSE CA180-400</masterLabel>
            <translation><!-- DASPERSE CA180-400 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DasaRealise</masterLabel>
            <translation><!-- DasaRealise --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EMANATE (Cardioversion)</masterLabel>
            <translation><!-- EMANATE (Cardioversion) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EVIDENS</masterLabel>
            <translation><!-- EVIDENS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GBM-143</masterLabel>
            <translation><!-- GBM-143 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GENERATION</masterLabel>
            <translation><!-- GENERATION --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Head&amp;Neck-141</masterLabel>
            <translation><!-- Head&amp;Neck-141 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ICoSRA</masterLabel>
            <translation><!-- ICoSRA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IM101-179</masterLabel>
            <translation><!-- IM101-179 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IM101-240 JIA</masterLabel>
            <translation><!-- IM101-240 JIA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IM101-301 SC in JIA</masterLabel>
            <translation><!-- IM101-301 SC in JIA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IM101-550 AVERT-2</masterLabel>
            <translation><!-- IM101-550 AVERT-2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IM127-028 Lupus Erythematosus</masterLabel>
            <translation><!-- IM127-028 Lupus Erythematosus --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IM140-103 ITP</masterLabel>
            <translation><!-- IM140-103 ITP --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMAGE</masterLabel>
            <translation><!-- IMAGE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Investigator Sponsored Research</masterLabel>
            <translation><!-- Investigator Sponsored Research --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lung 104</masterLabel>
            <translation><!-- Lung 104 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lung 156</masterLabel>
            <translation><!-- Lung 156 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lung-026</masterLabel>
            <translation><!-- Lung-026 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lung-171</masterLabel>
            <translation><!-- Lung-171 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lymphoma-139</masterLabel>
            <translation><!-- Lymphoma-139 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lymphoma-140</masterLabel>
            <translation><!-- Lymphoma-140 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>N-SqNSCLC-057</masterLabel>
            <translation><!-- N-SqNSCLC-057 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other trials</masterLabel>
            <translation><!-- Other trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PREAMBLE</masterLabel>
            <translation><!-- PREAMBLE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Pediatric CML trial 226</masterLabel>
            <translation><!-- Pediatric CML trial 226 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prostate 043</masterLabel>
            <translation><!-- Prostate 043 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prostate 095</masterLabel>
            <translation><!-- Prostate 095 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prostate 227</masterLabel>
            <translation><!-- Prostate 227 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RA-ILD</masterLabel>
            <translation><!-- RA-ILD --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RCC-025</masterLabel>
            <translation><!-- RCC-025 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RENAL-AF (Hemodialysis)</masterLabel>
            <translation><!-- RENAL-AF (Hemodialysis) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SAVOR</masterLabel>
            <translation><!-- SAVOR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SIMPLICITY</masterLabel>
            <translation><!-- SIMPLICITY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SqNSCLC-017</masterLabel>
            <translation><!-- SqNSCLC-017 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T1DM</masterLabel>
            <translation><!-- T1DM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VTE Treatment in Cancer</masterLabel>
            <translation><!-- VTE Treatment in Cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>mMel-067</masterLabel>
            <translation><!-- mMel-067 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>mMel-172</masterLabel>
            <translation><!-- mMel-172 --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Clinical Trial Protocol --></label>
        <name>Clinical_Trial_Protocol_BMS__c</name>
        <relationshipLabel><!-- Interaction Discussions --></relationshipLabel>
    </fields>
    <fields>
        <label><!-- Clinical Trial Site --></label>
        <name>Clinical_Trial_Site_BMS__c</name>
        <relationshipLabel><!-- Interaction Discussions --></relationshipLabel>
    </fields>
    <fields>
        <label>Yorumlar</label>
        <name>Comments__c</name>
    </fields>
    <fields>
        <label>İrtibat</label>
        <name>Contact_vod__c</name>
        <relationshipLabel>Ziyaret Müzakereleri(İrtibatlar)</relationshipLabel>
    </fields>
    <fields>
        <label><!-- Country --></label>
        <name>Country_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Country ID --></label>
        <name>Country_ID_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Deck ID --></label>
        <name>Deck_ID_BMS__c</name>
    </fields>
    <fields>
        <label>Ayrıntı Grubu</label>
        <name>Detail_Group_vod__c</name>
        <relationshipLabel>Aram Görüşmeleri (Ayrıntı Grubu)</relationshipLabel>
    </fields>
    <fields>
        <label>Müzakere Başlıkları</label>
        <name>Discussion_Topics__c</name>
        <picklistValues>
            <masterLabel>Discussion Topic 1</masterLabel>
            <translation><!-- Discussion Topic 1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discussion Topic 2</masterLabel>
            <translation><!-- Discussion Topic 2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discussion Topic 3</masterLabel>
            <translation><!-- Discussion Topic 3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discussion Topic 4</masterLabel>
            <translation><!-- Discussion Topic 4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discussion Topic 5</masterLabel>
            <translation><!-- Discussion Topic 5 --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Disease State: Proactive Deck --></label>
        <name>Disease_State_Proactive_Deck_BMS__c</name>
        <relationshipLabel><!-- Interaction Discussions --></relationshipLabel>
    </fields>
    <fields>
        <label><!-- Driver Reason --></label>
        <name>Driver_Reason_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>Baraclude_Achieved</masterLabel>
            <translation><!-- Baraclude_Achieved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Cost effective</masterLabel>
            <translation><!-- Cost effective --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DELETE</masterLabel>
            <translation><!-- DELETE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DM long term goal is to reduce mortality due to macro-vascular complication</masterLabel>
            <translation><!-- DM long term goal is to reduce mortality due to macro-vascular complication --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_DR_1_1_1</masterLabel>
            <translation><!-- Eliquis_DR_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_DR_1_1_2</masterLabel>
            <translation><!-- Eliquis_DR_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_DR_1_2_1</masterLabel>
            <translation><!-- Eliquis_DR_1_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_DR_1_2_2</masterLabel>
            <translation><!-- Eliquis_DR_1_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_DR_1_2_3</masterLabel>
            <translation><!-- Eliquis_DR_1_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_DR_1_2_4</masterLabel>
            <translation><!-- Eliquis_DR_1_2_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_DR_1_3_1</masterLabel>
            <translation><!-- Eliquis_DR_1_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_DR_1_4_1</masterLabel>
            <translation><!-- Eliquis_DR_1_4_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_DR_Achieved</masterLabel>
            <translation><!-- Glu_DR_Achieved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glucophage unique CV protection eviidence</masterLabel>
            <translation><!-- Glucophage unique CV protection eviidence --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Guideline recommend Metformin as the best choice of initial therapy</masterLabel>
            <translation><!-- Guideline recommend Metformin as the best choice of initial therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_1_1_1</masterLabel>
            <translation><!-- Monopril_DR_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_1_1_2</masterLabel>
            <translation><!-- Monopril_DR_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_1_1_3</masterLabel>
            <translation><!-- Monopril_DR_1_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_1_3_1</masterLabel>
            <translation><!-- Monopril_DR_1_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_1_3_2</masterLabel>
            <translation><!-- Monopril_DR_1_3_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_2_2_3</masterLabel>
            <translation><!-- Monopril_DR_2_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_2_3_1</masterLabel>
            <translation><!-- Monopril_DR_2_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_2_3_2</masterLabel>
            <translation><!-- Monopril_DR_2_3_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_3_2_1</masterLabel>
            <translation><!-- Monopril_DR_3_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_3_2_3</masterLabel>
            <translation><!-- Monopril_DR_3_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_3_3_1</masterLabel>
            <translation><!-- Monopril_DR_3_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_4_2_1</masterLabel>
            <translation><!-- Monopril_DR_4_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_4_2_2</masterLabel>
            <translation><!-- Monopril_DR_4_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_4_3_1</masterLabel>
            <translation><!-- Monopril_DR_4_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_Achieved</masterLabel>
            <translation><!-- Monopril_DR_Achieved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not Receive</masterLabel>
            <translation><!-- Not Receive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_1_1</masterLabel>
            <translation><!-- Onglyza_DR_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_1_2</masterLabel>
            <translation><!-- Onglyza_DR_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_1_3</masterLabel>
            <translation><!-- Onglyza_DR_1_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_1_4</masterLabel>
            <translation><!-- Onglyza_DR_1_1_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_2_1</masterLabel>
            <translation><!-- Onglyza_DR_1_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_2_2</masterLabel>
            <translation><!-- Onglyza_DR_1_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_2_3</masterLabel>
            <translation><!-- Onglyza_DR_1_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_2_4</masterLabel>
            <translation><!-- Onglyza_DR_1_2_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_3_1</masterLabel>
            <translation><!-- Onglyza_DR_1_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_3_3</masterLabel>
            <translation><!-- Onglyza_DR_1_3_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_2_2_5</masterLabel>
            <translation><!-- Onglyza_DR_2_2_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_2_3_2</masterLabel>
            <translation><!-- Onglyza_DR_2_3_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_2_3_4</masterLabel>
            <translation><!-- Onglyza_DR_2_3_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_1</masterLabel>
            <translation><!-- Paraplatin_DR_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_2</masterLabel>
            <translation><!-- Paraplatin_DR_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_3</masterLabel>
            <translation><!-- Paraplatin_DR_1_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_4</masterLabel>
            <translation><!-- Paraplatin_DR_1_1_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_5</masterLabel>
            <translation><!-- Paraplatin_DR_1_1_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_6</masterLabel>
            <translation><!-- Paraplatin_DR_1_1_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_7</masterLabel>
            <translation><!-- Paraplatin_DR_1_1_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_8</masterLabel>
            <translation><!-- Paraplatin_DR_1_1_8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_9</masterLabel>
            <translation><!-- Paraplatin_DR_1_1_9 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_2_1</masterLabel>
            <translation><!-- Paraplatin_DR_1_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_2_1_1</masterLabel>
            <translation><!-- Paraplatin_DR_2_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_2_1_2</masterLabel>
            <translation><!-- Paraplatin_DR_2_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_2_2_1</masterLabel>
            <translation><!-- Paraplatin_DR_2_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_2_2_2</masterLabel>
            <translation><!-- Paraplatin_DR_2_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Poor effect of Metformin Generic’s low dosage</masterLabel>
            <translation><!-- Poor effect of Metformin Generic’s low dosage --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Receive</masterLabel>
            <translation><!-- Receive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_1_1</masterLabel>
            <translation><!-- Taxol_DR_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_1_2</masterLabel>
            <translation><!-- Taxol_DR_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_1_3</masterLabel>
            <translation><!-- Taxol_DR_1_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_1_4</masterLabel>
            <translation><!-- Taxol_DR_1_1_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_1_5</masterLabel>
            <translation><!-- Taxol_DR_1_1_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_1_6</masterLabel>
            <translation><!-- Taxol_DR_1_1_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_2_1</masterLabel>
            <translation><!-- Taxol_DR_1_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_2_2</masterLabel>
            <translation><!-- Taxol_DR_1_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_3_1</masterLabel>
            <translation><!-- Taxol_DR_1_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_1_1</masterLabel>
            <translation><!-- Taxol_DR_2_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_1_3</masterLabel>
            <translation><!-- Taxol_DR_2_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_1_4</masterLabel>
            <translation><!-- Taxol_DR_2_1_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_1_5</masterLabel>
            <translation><!-- Taxol_DR_2_1_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_1_6</masterLabel>
            <translation><!-- Taxol_DR_2_1_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_1_7</masterLabel>
            <translation><!-- Taxol_DR_2_1_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_1_8</masterLabel>
            <translation><!-- Taxol_DR_2_1_8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_1_9</masterLabel>
            <translation><!-- Taxol_DR_2_1_9 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_2_1</masterLabel>
            <translation><!-- Taxol_DR_2_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_2_2</masterLabel>
            <translation><!-- Taxol_DR_2_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_2_4</masterLabel>
            <translation><!-- Taxol_DR_2_2_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_2_5</masterLabel>
            <translation><!-- Taxol_DR_2_2_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_3_1</masterLabel>
            <translation><!-- Taxol_DR_2_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>The selection of medication should be minimizing the risk and severity of hypoglycemia, weight gain and FPG/PPG/HbA1c control</masterLabel>
            <translation><!-- The selection of medication should be minimizing the risk and severity of hypoglycemia, weight gain and FPG/PPG/HbA1c control --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Engagement Activities --></label>
        <lookupFilter>
            <errorMessage><!-- Engagement Activities selected must either be in Planned or In Progress Status &amp; Assigned to should be Medical. --></errorMessage>
        </lookupFilter>
        <name>Engagement_Activities_BMS_EMEA__c</name>
        <relationshipLabel><!-- Interaction Discussions (Engagement Activities) --></relationshipLabel>
    </fields>
    <fields>
        <label>Tüzel Kişi Referans Kimliği</label>
        <name>Entity_Reference_Id_vod__c</name>
    </fields>
    <fields>
        <label><!-- Feedback_OTC --></label>
        <name>Feedback_BMS_OTC_CN__c</name>
        <picklistValues>
            <masterLabel>Buf_Day_FB_1</masterLabel>
            <translation><!-- Buf_Day_FB_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_FB_3</masterLabel>
            <translation><!-- Buf_Day_FB_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_FB_4</masterLabel>
            <translation><!-- Buf_Day_FB_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_FB_5</masterLabel>
            <translation><!-- Buf_Day_FB_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_FB_6</masterLabel>
            <translation><!-- Buf_Day_FB_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_FB_1</masterLabel>
            <translation><!-- Buf_Plus_FB_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_FB_2</masterLabel>
            <translation><!-- Buf_Plus_FB_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_FB_3</masterLabel>
            <translation><!-- Buf_Plus_FB_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_FB_4</masterLabel>
            <translation><!-- Buf_Plus_FB_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Children_FB_1</masterLabel>
            <translation><!-- Children_FB_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Children_FB_2</masterLabel>
            <translation><!-- Children_FB_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Children_FB_3</masterLabel>
            <translation><!-- Children_FB_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Children_FB_4</masterLabel>
            <translation><!-- Children_FB_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DELETE</masterLabel>
            <translation><!-- DELETE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_FB_1</masterLabel>
            <translation><!-- Eliquis_FB_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_FB_2</masterLabel>
            <translation><!-- Eliquis_FB_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_FB_3</masterLabel>
            <translation><!-- Eliquis_FB_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_FB_4</masterLabel>
            <translation><!-- Eliquis_FB_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_FB_5</masterLabel>
            <translation><!-- Eliquis_FB_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_FB_6</masterLabel>
            <translation><!-- Eliquis_FB_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_FB_7</masterLabel>
            <translation><!-- Eliquis_FB_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>FB_Achieved</masterLabel>
            <translation><!-- FB_Achieved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>FB_NOT_Achieved</masterLabel>
            <translation><!-- FB_NOT_Achieved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_1</masterLabel>
            <translation><!-- Glu_FB_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_2</masterLabel>
            <translation><!-- Glu_FB_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_3</masterLabel>
            <translation><!-- Glu_FB_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_4</masterLabel>
            <translation><!-- Glu_FB_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_5</masterLabel>
            <translation><!-- Glu_FB_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_6</masterLabel>
            <translation><!-- Glu_FB_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_7</masterLabel>
            <translation><!-- Glu_FB_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_8</masterLabel>
            <translation><!-- Glu_FB_8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_9</masterLabel>
            <translation><!-- Glu_FB_9 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_1</masterLabel>
            <translation><!-- Monopril_FB_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_10</masterLabel>
            <translation><!-- Monopril_FB_10 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_11</masterLabel>
            <translation><!-- Monopril_FB_11 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_12</masterLabel>
            <translation><!-- Monopril_FB_12 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_13</masterLabel>
            <translation><!-- Monopril_FB_13 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_14</masterLabel>
            <translation><!-- Monopril_FB_14 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_15</masterLabel>
            <translation><!-- Monopril_FB_15 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_16</masterLabel>
            <translation><!-- Monopril_FB_16 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_17</masterLabel>
            <translation><!-- Monopril_FB_17 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_2</masterLabel>
            <translation><!-- Monopril_FB_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_3</masterLabel>
            <translation><!-- Monopril_FB_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_4</masterLabel>
            <translation><!-- Monopril_FB_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_5</masterLabel>
            <translation><!-- Monopril_FB_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_6</masterLabel>
            <translation><!-- Monopril_FB_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_7</masterLabel>
            <translation><!-- Monopril_FB_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_8</masterLabel>
            <translation><!-- Monopril_FB_8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_9</masterLabel>
            <translation><!-- Monopril_FB_9 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NoValue</masterLabel>
            <translation><!-- NoValue --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_1</masterLabel>
            <translation><!-- Onglyza_FB_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_10</masterLabel>
            <translation><!-- Onglyza_FB_10 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_11</masterLabel>
            <translation><!-- Onglyza_FB_11 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_12</masterLabel>
            <translation><!-- Onglyza_FB_12 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_13</masterLabel>
            <translation><!-- Onglyza_FB_13 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_14</masterLabel>
            <translation><!-- Onglyza_FB_14 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_15</masterLabel>
            <translation><!-- Onglyza_FB_15 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_16</masterLabel>
            <translation><!-- Onglyza_FB_16 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_17</masterLabel>
            <translation><!-- Onglyza_FB_17 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_2</masterLabel>
            <translation><!-- Onglyza_FB_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_3</masterLabel>
            <translation><!-- Onglyza_FB_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_4</masterLabel>
            <translation><!-- Onglyza_FB_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_5</masterLabel>
            <translation><!-- Onglyza_FB_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_6</masterLabel>
            <translation><!-- Onglyza_FB_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_7</masterLabel>
            <translation><!-- Onglyza_FB_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_8</masterLabel>
            <translation><!-- Onglyza_FB_8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_9</masterLabel>
            <translation><!-- Onglyza_FB_9 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_1</masterLabel>
            <translation><!-- Paraplatin_FB_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_10</masterLabel>
            <translation><!-- Paraplatin_FB_10 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_11</masterLabel>
            <translation><!-- Paraplatin_FB_11 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_12</masterLabel>
            <translation><!-- Paraplatin_FB_12 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_13</masterLabel>
            <translation><!-- Paraplatin_FB_13 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_14</masterLabel>
            <translation><!-- Paraplatin_FB_14 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_15</masterLabel>
            <translation><!-- Paraplatin_FB_15 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_16</masterLabel>
            <translation><!-- Paraplatin_FB_16 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_2</masterLabel>
            <translation><!-- Paraplatin_FB_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_3</masterLabel>
            <translation><!-- Paraplatin_FB_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_4</masterLabel>
            <translation><!-- Paraplatin_FB_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_5</masterLabel>
            <translation><!-- Paraplatin_FB_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_6</masterLabel>
            <translation><!-- Paraplatin_FB_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_7</masterLabel>
            <translation><!-- Paraplatin_FB_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_8</masterLabel>
            <translation><!-- Paraplatin_FB_8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_9</masterLabel>
            <translation><!-- Paraplatin_FB_9 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_1</masterLabel>
            <translation><!-- Taxol_FB_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_10</masterLabel>
            <translation><!-- Taxol_FB_10 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_11</masterLabel>
            <translation><!-- Taxol_FB_11 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_12</masterLabel>
            <translation><!-- Taxol_FB_12 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_13</masterLabel>
            <translation><!-- Taxol_FB_13 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_14</masterLabel>
            <translation><!-- Taxol_FB_14 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_15</masterLabel>
            <translation><!-- Taxol_FB_15 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_16</masterLabel>
            <translation><!-- Taxol_FB_16 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_17</masterLabel>
            <translation><!-- Taxol_FB_17 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_18</masterLabel>
            <translation><!-- Taxol_FB_18 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_19</masterLabel>
            <translation><!-- Taxol_FB_19 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_2</masterLabel>
            <translation><!-- Taxol_FB_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_3</masterLabel>
            <translation><!-- Taxol_FB_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_4</masterLabel>
            <translation><!-- Taxol_FB_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_5</masterLabel>
            <translation><!-- Taxol_FB_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_6</masterLabel>
            <translation><!-- Taxol_FB_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_7</masterLabel>
            <translation><!-- Taxol_FB_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_8</masterLabel>
            <translation><!-- Taxol_FB_8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_9</masterLabel>
            <translation><!-- Taxol_FB_9 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_1</masterLabel>
            <translation><!-- Theragran_G_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_2</masterLabel>
            <translation><!-- Theragran_G_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_3</masterLabel>
            <translation><!-- Theragran_G_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_JR_1</masterLabel>
            <translation><!-- Theragran_JR_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_JR_2</masterLabel>
            <translation><!-- Theragran_JR_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VB_Complex_FB_1</masterLabel>
            <translation><!-- VB_Complex_FB_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VB_Complex_FB_2</masterLabel>
            <translation><!-- VB_Complex_FB_2 --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Incremental Shift --></label>
        <name>Incremental_Shift_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>Added dosage to 1.5-2g to all T2DM patients.</masterLabel>
            <translation><!-- Added dosage to 1.5-2g to all T2DM patients. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Adding Taxane (3-week) to anthracycline regimen as 1st line adjuvant chemotherapy in EBC.</masterLabel>
            <translation><!-- Adding Taxane (3-week) to anthracycline regimen as 1st line adjuvant chemotherapy in EBC. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_IS_1_2</masterLabel>
            <translation><!-- Baraclude_IS_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_IS_1_3</masterLabel>
            <translation><!-- Baraclude_IS_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_IS_1_4</masterLabel>
            <translation><!-- Baraclude_IS_1_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_IS_1_5</masterLabel>
            <translation><!-- Baraclude_IS_1_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_IS_2_1</masterLabel>
            <translation><!-- Baraclude_IS_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_IS_2_2</masterLabel>
            <translation><!-- Baraclude_IS_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_IS_2_3</masterLabel>
            <translation><!-- Baraclude_IS_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_IS_2_4</masterLabel>
            <translation><!-- Baraclude_IS_2_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_IS_1_1</masterLabel>
            <translation><!-- Eliquis_IS_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_IS_1_2</masterLabel>
            <translation><!-- Eliquis_IS_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_IS_1_3</masterLabel>
            <translation><!-- Eliquis_IS_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_IS_1_4</masterLabel>
            <translation><!-- Eliquis_IS_1_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu will be prescribed to new diagnosed T2DM patients as preferred initial therapy</masterLabel>
            <translation><!-- Glu will be prescribed to new diagnosed T2DM patients as preferred initial therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_IS_1_1</masterLabel>
            <translation><!-- Glu_IS_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_1_1</masterLabel>
            <translation><!-- Monopril_IS_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_1_2</masterLabel>
            <translation><!-- Monopril_IS_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_1_3</masterLabel>
            <translation><!-- Monopril_IS_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_1_4</masterLabel>
            <translation><!-- Monopril_IS_1_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_2_1</masterLabel>
            <translation><!-- Monopril_IS_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_2_2</masterLabel>
            <translation><!-- Monopril_IS_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_2_3</masterLabel>
            <translation><!-- Monopril_IS_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_2_4</masterLabel>
            <translation><!-- Monopril_IS_2_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_3_1</masterLabel>
            <translation><!-- Monopril_IS_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_3_2</masterLabel>
            <translation><!-- Monopril_IS_3_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_3_3</masterLabel>
            <translation><!-- Monopril_IS_3_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_3_4</masterLabel>
            <translation><!-- Monopril_IS_3_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_4_1</masterLabel>
            <translation><!-- Monopril_IS_4_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_4_2</masterLabel>
            <translation><!-- Monopril_IS_4_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_4_3</masterLabel>
            <translation><!-- Monopril_IS_4_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_4_4</masterLabel>
            <translation><!-- Monopril_IS_4_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Only when concern the side effect about SU or AGI,then choice Onglyza for new diagnosed T2DM patients</masterLabel>
            <translation><!-- Only when concern the side effect about SU or AGI,then choice Onglyza for new diagnosed T2DM patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Only when concern the side effect about SU or AGI,then choice add Onglyza on Met for patient who Glucose uncontrol with mono Met dosage 1500mg above</masterLabel>
            <translation><!-- Only when concern the side effect about SU or AGI,then choice add Onglyza on Met for patient who Glucose uncontrol with mono Met dosage 1500mg above --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_IS_1_1</masterLabel>
            <translation><!-- Paraplatin_IS_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_IS_1_2</masterLabel>
            <translation><!-- Paraplatin_IS_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_IS_2_1</masterLabel>
            <translation><!-- Paraplatin_IS_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_IS_2_2</masterLabel>
            <translation><!-- Paraplatin_IS_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_IS_2_3</masterLabel>
            <translation><!-- Paraplatin_IS_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prescribe Glu to all T2DM patients on whole treatment.</masterLabel>
            <translation><!-- Prescribe Glu to all T2DM patients on whole treatment. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regard Onglyza as the first choice for new diagnosed T2DM patients</masterLabel>
            <translation><!-- Regard Onglyza as the first choice for new diagnosed T2DM patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regard Onglyza as the first choice for the patient who Glucose uncontrol with mono Met dosage 1500mg above</masterLabel>
            <translation><!-- Regard Onglyza as the first choice for the patient who Glucose uncontrol with mono Met dosage 1500mg above --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regular add Onglyza on Met for patient who Glucose uncontrol with mono Met dosage 1500mg above</masterLabel>
            <translation><!-- Regular add Onglyza on Met for patient who Glucose uncontrol with mono Met dosage 1500mg above --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regular add SU or AGI on Met for patient who Glucose uncontrol with mono Met dosage 1500mg above</masterLabel>
            <translation><!-- Regular add SU or AGI on Met for patient who Glucose uncontrol with mono Met dosage 1500mg above --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regular use Onglyza for new diagnosed T2DM patients</masterLabel>
            <translation><!-- Regular use Onglyza for new diagnosed T2DM patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regular use SU or AGI for new diagnosed T2DM patients</masterLabel>
            <translation><!-- Regular use SU or AGI for new diagnosed T2DM patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_IS_1_1</masterLabel>
            <translation><!-- Taxol_IS_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_IS_1_2</masterLabel>
            <translation><!-- Taxol_IS_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_IS_1_3</masterLabel>
            <translation><!-- Taxol_IS_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_IS_2_1</masterLabel>
            <translation><!-- Taxol_IS_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_IS_2_2</masterLabel>
            <translation><!-- Taxol_IS_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_IS_2_3</masterLabel>
            <translation><!-- Taxol_IS_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_IS_2_4</masterLabel>
            <translation><!-- Taxol_IS_2_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Treat CHB but not use ETV</masterLabel>
            <translation><!-- Treat CHB but not use ETV --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label>Belirti</label>
        <name>Indication__c</name>
        <picklistValues>
            <masterLabel>Indication 1</masterLabel>
            <translation>Gösterge 1</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Indication 2</masterLabel>
            <translation>Gösterge 2</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Indication 3</masterLabel>
            <translation>Gösterge 3</translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Interaction Topic --></label>
        <name>Interaction_Topic_BMS__c</name>
        <picklistValues>
            <masterLabel>1- Profiling</masterLabel>
            <translation><!-- 1- Profiling --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>1-Pipeline Discussion</masterLabel>
            <translation><!-- 1-Pipeline Discussion --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>2- Introduction</masterLabel>
            <translation><!-- 2- Introduction --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>2-Disease Awareness</masterLabel>
            <translation><!-- 2-Disease Awareness --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>3- Medical Communication Topic</masterLabel>
            <translation><!-- 3- Medical Communication Topic --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>4- Clinical Trial</masterLabel>
            <translation><!-- 4- Clinical Trial --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- Advisory Board</masterLabel>
            <translation><!-- 5- Advisory Board --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- Compassionate Use Support</masterLabel>
            <translation><!-- 5- Compassionate Use Support --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- Congress Debrief</masterLabel>
            <translation><!-- 5- Congress Debrief --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- Early Access Program (EAP)</masterLabel>
            <translation><!-- 5- Early Access Program (EAP) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- Market Access Support</masterLabel>
            <translation><!-- 5- Market Access Support --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- Med Info Department Follow-Up</masterLabel>
            <translation><!-- 5- Med Info Department Follow-Up --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- Pipeline</masterLabel>
            <translation><!-- 5- Pipeline --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- RMP Related</masterLabel>
            <translation><!-- 5- RMP Related --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- Speaker/Consultant Prep</masterLabel>
            <translation><!-- 5- Speaker/Consultant Prep --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ad Board Related</masterLabel>
            <translation><!-- Ad Board Related --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Advisory Board</masterLabel>
            <translation><!-- Advisory Board --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Advisory Board_cn</masterLabel>
            <translation><!-- Advisory Board_cn --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS Clinical Trial_cn</masterLabel>
            <translation><!-- BMS Clinical Trial_cn --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial</masterLabel>
            <translation><!-- Clinical Trial --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial - 1st Qtr Visit</masterLabel>
            <translation><!-- Clinical Trial - 1st Qtr Visit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial - 2nd Qtr Visit</masterLabel>
            <translation><!-- Clinical Trial - 2nd Qtr Visit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial - 3rd Qtr Visit</masterLabel>
            <translation><!-- Clinical Trial - 3rd Qtr Visit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial - 4th Qtr Visit</masterLabel>
            <translation><!-- Clinical Trial - 4th Qtr Visit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial - Pre Initiation / Non-Scope Related</masterLabel>
            <translation><!-- Clinical Trial - Pre Initiation / Non-Scope Related --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial Investigator Meeting</masterLabel>
            <translation><!-- Clinical Trial Investigator Meeting --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial Pre-Initiation Visit / Non-Scope</masterLabel>
            <translation><!-- Clinical Trial Pre-Initiation Visit / Non-Scope --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial Visit</masterLabel>
            <translation><!-- Clinical Trial Visit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Compassionate Use Support</masterLabel>
            <translation><!-- Compassionate Use Support --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Congress Debrief</masterLabel>
            <translation><!-- Congress Debrief --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Congress invitation</masterLabel>
            <translation>Kongre Takipçisi</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Disease State - Proactive</masterLabel>
            <translation><!-- Disease State - Proactive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Disease State - Reactive</masterLabel>
            <translation><!-- Disease State - Reactive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Disease State Discussion</masterLabel>
            <translation><!-- Disease State Discussion --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Early Access Program (EAP)</masterLabel>
            <translation><!-- Early Access Program (EAP) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Expanded Access Program</masterLabel>
            <translation><!-- Expanded Access Program --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Formulary Discussion_cn</masterLabel>
            <translation><!-- Formulary Discussion_cn --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Grants Discussion</masterLabel>
            <translation><!-- Grants Discussion --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Health Outcomes</masterLabel>
            <translation><!-- Health Outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ISR Request</masterLabel>
            <translation><!-- ISR Request --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Introduction</masterLabel>
            <translation><!-- Introduction --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Investigator Sponsored Trial_cn</masterLabel>
            <translation><!-- Investigator Sponsored Trial_cn --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Market Access</masterLabel>
            <translation><!-- Market Access --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Market Access - Formulary / Slide Presentation</masterLabel>
            <translation><!-- Market Access - Formulary / Slide Presentation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Market Access - Outcomes Research</masterLabel>
            <translation><!-- Market Access - Outcomes Research --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Market Access - Pipeline</masterLabel>
            <translation><!-- Market Access - Pipeline --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Market Access Discussion_cn</masterLabel>
            <translation><!-- Market Access Discussion_cn --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Market Access Formulary</masterLabel>
            <translation><!-- Market Access Formulary --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Market Access Related</masterLabel>
            <translation><!-- Market Access Related --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Med Info Department Follow-Up</masterLabel>
            <translation><!-- Med Info Department Follow-Up --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Med Info Dept. Follow Up</masterLabel>
            <translation><!-- Med Info Dept. Follow Up --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Med Info follow-up_cn</masterLabel>
            <translation><!-- Med Info follow-up_cn --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Medical Strategy Discussion</masterLabel>
            <translation><!-- Medical Strategy Discussion --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Patient Access Program</masterLabel>
            <translation><!-- Patient Access Program --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Pipeline</masterLabel>
            <translation><!-- Pipeline --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Pipeline (Non-Market Access)</masterLabel>
            <translation><!-- Pipeline (Non-Market Access) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Product - Proactive</masterLabel>
            <translation><!-- Product - Proactive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Product - Reactive</masterLabel>
            <translation><!-- Product - Reactive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Product Discussion</masterLabel>
            <translation><!-- Product Discussion --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Profiling</masterLabel>
            <translation><!-- Profiling --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Publication Strategy</masterLabel>
            <translation><!-- Publication Strategy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Publication_cn</masterLabel>
            <translation><!-- Publication_cn --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SA on Demand</masterLabel>
            <translation><!-- SA on Demand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Scientific Data Exchange</masterLabel>
            <translation><!-- Scientific Data Exchange --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Scientific Exchange_cn</masterLabel>
            <translation><!-- Scientific Exchange_cn --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Scientific Profiling</masterLabel>
            <translation><!-- Scientific Profiling --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Speaker Evaluation</masterLabel>
            <translation><!-- Speaker Evaluation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Speaker Training</masterLabel>
            <translation><!-- Speaker Training --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Speaker Training - Evaluation</masterLabel>
            <translation><!-- Speaker Training - Evaluation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Speaker Training - Formal</masterLabel>
            <translation><!-- Speaker Training - Formal --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Speaker Training - Informal</masterLabel>
            <translation><!-- Speaker Training - Informal --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Speaker Training_cn</masterLabel>
            <translation><!-- Speaker Training_cn --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Speaker/Consultant Prep</masterLabel>
            <translation><!-- Speaker/Consultant Prep --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Thought Leader Profiling_cn</masterLabel>
            <translation><!-- Thought Leader Profiling_cn --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>iPlan Program</masterLabel>
            <translation><!-- iPlan Program --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Interaction Type --></label>
        <name>Interaction_Type_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>Proactive</masterLabel>
            <translation><!-- Proactive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Proactive_BARACLUDE</masterLabel>
            <translation><!-- Proactive_BARACLUDE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Proactive_BYETTA</masterLabel>
            <translation><!-- Proactive_BYETTA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Proactive_Eliquis</masterLabel>
            <translation><!-- Proactive_Eliquis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Proactive_FORXIGA</masterLabel>
            <translation><!-- Proactive_FORXIGA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Proactive_ONGLYZA</masterLabel>
            <translation><!-- Proactive_ONGLYZA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Proactive_ORENCIA</masterLabel>
            <translation><!-- Proactive_ORENCIA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Proactive_SPRYCEL</masterLabel>
            <translation><!-- Proactive_SPRYCEL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactive</masterLabel>
            <translation><!-- Reactive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactive_BARACLUDE</masterLabel>
            <translation><!-- Reactive_BARACLUDE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactive_BYETTA</masterLabel>
            <translation><!-- Reactive_BYETTA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactive_Eliquis</masterLabel>
            <translation><!-- Reactive_Eliquis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactive_FORXIGA</masterLabel>
            <translation><!-- Reactive_FORXIGA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactive_ONGLYZA</masterLabel>
            <translation><!-- Reactive_ONGLYZA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactive_ORENCIA</masterLabel>
            <translation><!-- Reactive_ORENCIA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactive_SPRYCEL</masterLabel>
            <translation><!-- Reactive_SPRYCEL --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Is Achieved ? --></label>
        <name>Is_Achieved_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label>Ana Ziyaret mi?</label>
        <name>Is_Parent_Call_vod__c</name>
    </fields>
    <fields>
        <label><!-- Key Messages --></label>
        <name>Key_Messages_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>50 years experience, body weight neutral, rare hypoglycemia</masterLabel>
            <translation><!-- 50 years experience, body weight neutral, rare hypoglycemia --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Already Achieved：Protect you today, for the future outcome</masterLabel>
            <translation><!-- Already Achieved：Protect you today, for the future outcome --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM380</masterLabel>
            <translation><!-- CN_KM380 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM381</masterLabel>
            <translation><!-- CN_KM381 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM382</masterLabel>
            <translation><!-- CN_KM382 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM383</masterLabel>
            <translation><!-- CN_KM383 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM384</masterLabel>
            <translation><!-- CN_KM384 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM385</masterLabel>
            <translation><!-- CN_KM385 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM386</masterLabel>
            <translation><!-- CN_KM386 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM387</masterLabel>
            <translation><!-- CN_KM387 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM389</masterLabel>
            <translation><!-- CN_KM389 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM390</masterLabel>
            <translation><!-- CN_KM390 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM391</masterLabel>
            <translation><!-- CN_KM391 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM393</masterLabel>
            <translation><!-- CN_KM393 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM395</masterLabel>
            <translation><!-- CN_KM395 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM396</masterLabel>
            <translation><!-- CN_KM396 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM397</masterLabel>
            <translation><!-- CN_KM397 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM400</masterLabel>
            <translation><!-- CN_KM400 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM401</masterLabel>
            <translation><!-- CN_KM401 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM402</masterLabel>
            <translation><!-- CN_KM402 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM403</masterLabel>
            <translation><!-- CN_KM403 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM404</masterLabel>
            <translation><!-- CN_KM404 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM405</masterLabel>
            <translation><!-- CN_KM405 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM406</masterLabel>
            <translation><!-- CN_KM406 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM407</masterLabel>
            <translation><!-- CN_KM407 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM409</masterLabel>
            <translation><!-- CN_KM409 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM410</masterLabel>
            <translation><!-- CN_KM410 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DELETE</masterLabel>
            <translation><!-- DELETE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_1_1</masterLabel>
            <translation><!-- Eliquis_KM_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_1_2</masterLabel>
            <translation><!-- Eliquis_KM_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_2_1</masterLabel>
            <translation><!-- Eliquis_KM_1_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_2_2</masterLabel>
            <translation><!-- Eliquis_KM_1_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_2_3</masterLabel>
            <translation><!-- Eliquis_KM_1_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_3_1</masterLabel>
            <translation><!-- Eliquis_KM_1_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_3_2</masterLabel>
            <translation><!-- Eliquis_KM_1_3_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_3_3</masterLabel>
            <translation><!-- Eliquis_KM_1_3_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_4_1</masterLabel>
            <translation><!-- Eliquis_KM_1_4_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Evidence demonstrate that long term treatement with Glucophage provide Long-term benefit</masterLabel>
            <translation><!-- Evidence demonstrate that long term treatement with Glucophage provide Long-term benefit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glucophage effective on FPG, PPG and HbA1c</masterLabel>
            <translation><!-- Glucophage effective on FPG, PPG and HbA1c --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glucophage optimal dosage (2000mg / day) achieve maximum efficacy and lowest side effect</masterLabel>
            <translation><!-- Glucophage optimal dosage (2000mg / day) achieve maximum efficacy and lowest side effect --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glucophage provide long-term cardiovascular protection, improve the quality of life and reduce mortality</masterLabel>
            <translation><!-- Glucophage provide long-term cardiovascular protection, improve the quality of life and reduce mortality --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Guideline recommend Glucophage as the only initial therapy for new diagnosed T2DM patients</masterLabel>
            <translation><!-- Guideline recommend Glucophage as the only initial therapy for new diagnosed T2DM patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_1_1_1</masterLabel>
            <translation><!-- Monopril_KeyMsg_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_1_2_1</masterLabel>
            <translation><!-- Monopril_KeyMsg_1_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_1_2_2</masterLabel>
            <translation><!-- Monopril_KeyMsg_1_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_1_3_1</masterLabel>
            <translation><!-- Monopril_KeyMsg_1_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_1_3_2</masterLabel>
            <translation><!-- Monopril_KeyMsg_1_3_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_1_3_3</masterLabel>
            <translation><!-- Monopril_KeyMsg_1_3_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_2_1_1</masterLabel>
            <translation><!-- Monopril_KeyMsg_2_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_2_2_1</masterLabel>
            <translation><!-- Monopril_KeyMsg_2_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_2_2_2</masterLabel>
            <translation><!-- Monopril_KeyMsg_2_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_2_3_1</masterLabel>
            <translation><!-- Monopril_KeyMsg_2_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_2_3_2</masterLabel>
            <translation><!-- Monopril_KeyMsg_2_3_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_2_3_3</masterLabel>
            <translation><!-- Monopril_KeyMsg_2_3_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_3_1_1</masterLabel>
            <translation><!-- Monopril_KeyMsg_3_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_3_2_1</masterLabel>
            <translation><!-- Monopril_KeyMsg_3_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_3_2_2</masterLabel>
            <translation><!-- Monopril_KeyMsg_3_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_3_2_3</masterLabel>
            <translation><!-- Monopril_KeyMsg_3_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_3_3_1</masterLabel>
            <translation><!-- Monopril_KeyMsg_3_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_3_3_2</masterLabel>
            <translation><!-- Monopril_KeyMsg_3_3_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_3_3_3</masterLabel>
            <translation><!-- Monopril_KeyMsg_3_3_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_3_4_1</masterLabel>
            <translation><!-- Monopril_KeyMsg_3_4_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_4_2_1</masterLabel>
            <translation><!-- Monopril_KeyMsg_4_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_4_2_2</masterLabel>
            <translation><!-- Monopril_KeyMsg_4_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_4_2_3</masterLabel>
            <translation><!-- Monopril_KeyMsg_4_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_4_3_1</masterLabel>
            <translation><!-- Monopril_KeyMsg_4_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_4_3_2</masterLabel>
            <translation><!-- Monopril_KeyMsg_4_3_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_4_3_3</masterLabel>
            <translation><!-- Monopril_KeyMsg_4_3_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_1_1_1</masterLabel>
            <translation><!-- Onglyza_KeyMsg_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_1_1_2</masterLabel>
            <translation><!-- Onglyza_KeyMsg_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_1_1_3</masterLabel>
            <translation><!-- Onglyza_KeyMsg_1_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_1_2_3</masterLabel>
            <translation><!-- Onglyza_KeyMsg_1_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_1_3_1</masterLabel>
            <translation><!-- Onglyza_KeyMsg_1_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_1_3_3</masterLabel>
            <translation><!-- Onglyza_KeyMsg_1_3_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_2_1_1</masterLabel>
            <translation><!-- Onglyza_KeyMsg_2_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_2_1_2</masterLabel>
            <translation><!-- Onglyza_KeyMsg_2_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_2_1_3</masterLabel>
            <translation><!-- Onglyza_KeyMsg_2_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_1_1_1</masterLabel>
            <translation><!-- Paraplatin_KM_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_1_1_2</masterLabel>
            <translation><!-- Paraplatin_KM_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_1_1_3</masterLabel>
            <translation><!-- Paraplatin_KM_1_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_1_1_4</masterLabel>
            <translation><!-- Paraplatin_KM_1_1_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_1_1_5</masterLabel>
            <translation><!-- Paraplatin_KM_1_1_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_1_1_6</masterLabel>
            <translation><!-- Paraplatin_KM_1_1_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_1_2_1</masterLabel>
            <translation><!-- Paraplatin_KM_1_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_2_1_1</masterLabel>
            <translation><!-- Paraplatin_KM_2_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_2_1_2</masterLabel>
            <translation><!-- Paraplatin_KM_2_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_2_2_1</masterLabel>
            <translation><!-- Paraplatin_KM_2_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_2_2_2</masterLabel>
            <translation><!-- Paraplatin_KM_2_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_1_1_1</masterLabel>
            <translation><!-- Taxol_KM_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_1_1_2</masterLabel>
            <translation><!-- Taxol_KM_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_1_1_3</masterLabel>
            <translation><!-- Taxol_KM_1_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_1_1_4</masterLabel>
            <translation><!-- Taxol_KM_1_1_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_1_2_1</masterLabel>
            <translation><!-- Taxol_KM_1_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_1_3_1</masterLabel>
            <translation><!-- Taxol_KM_1_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_2_1_3</masterLabel>
            <translation><!-- Taxol_KM_2_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_2_1_4</masterLabel>
            <translation><!-- Taxol_KM_2_1_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_2_2_3</masterLabel>
            <translation><!-- Taxol_KM_2_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_2_2_4</masterLabel>
            <translation><!-- Taxol_KM_2_2_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_2_3_1</masterLabel>
            <translation><!-- Taxol_KM_2_3_1 --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Key_Messages OTC --></label>
        <name>Key_Messages_OTC_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>Baraclude_KM_1</masterLabel>
            <translation><!-- Baraclude_KM_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_10</masterLabel>
            <translation><!-- Baraclude_KM_10 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_11</masterLabel>
            <translation><!-- Baraclude_KM_11 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_12</masterLabel>
            <translation><!-- Baraclude_KM_12 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_13</masterLabel>
            <translation><!-- Baraclude_KM_13 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_14</masterLabel>
            <translation><!-- Baraclude_KM_14 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_15</masterLabel>
            <translation><!-- Baraclude_KM_15 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_16</masterLabel>
            <translation><!-- Baraclude_KM_16 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_17</masterLabel>
            <translation><!-- Baraclude_KM_17 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_18</masterLabel>
            <translation><!-- Baraclude_KM_18 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_2</masterLabel>
            <translation><!-- Baraclude_KM_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_3</masterLabel>
            <translation><!-- Baraclude_KM_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_4</masterLabel>
            <translation><!-- Baraclude_KM_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_5</masterLabel>
            <translation><!-- Baraclude_KM_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_6</masterLabel>
            <translation><!-- Baraclude_KM_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_7</masterLabel>
            <translation><!-- Baraclude_KM_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_8</masterLabel>
            <translation><!-- Baraclude_KM_8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_9</masterLabel>
            <translation><!-- Baraclude_KM_9 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_KM_1</masterLabel>
            <translation><!-- Buf_Day_KM_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_KM_2</masterLabel>
            <translation><!-- Buf_Day_KM_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_KM_3</masterLabel>
            <translation><!-- Buf_Day_KM_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_KM_4</masterLabel>
            <translation><!-- Buf_Day_KM_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_KM_5</masterLabel>
            <translation><!-- Buf_Day_KM_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_KM_6</masterLabel>
            <translation><!-- Buf_Day_KM_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_KM_1</masterLabel>
            <translation><!-- Buf_Plus_KM_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_KM_2</masterLabel>
            <translation><!-- Buf_Plus_KM_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_KM_3</masterLabel>
            <translation><!-- Buf_Plus_KM_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_KM_4</masterLabel>
            <translation><!-- Buf_Plus_KM_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_KM_5</masterLabel>
            <translation><!-- Buf_Plus_KM_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Children_KM_1</masterLabel>
            <translation><!-- Children_KM_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Children_KM_2</masterLabel>
            <translation><!-- Children_KM_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Children_KM_3</masterLabel>
            <translation><!-- Children_KM_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1</masterLabel>
            <translation><!-- Eliquis_KM_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_2</masterLabel>
            <translation><!-- Eliquis_KM_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_3</masterLabel>
            <translation><!-- Eliquis_KM_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_4</masterLabel>
            <translation><!-- Eliquis_KM_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_5</masterLabel>
            <translation><!-- Eliquis_KM_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_6</masterLabel>
            <translation><!-- Eliquis_KM_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_KM_1</masterLabel>
            <translation><!-- Glu_KM_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_KM_2</masterLabel>
            <translation><!-- Glu_KM_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_KM_3</masterLabel>
            <translation><!-- Glu_KM_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_KM_4</masterLabel>
            <translation><!-- Glu_KM_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_KM_5</masterLabel>
            <translation><!-- Glu_KM_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_KM_6</masterLabel>
            <translation><!-- Glu_KM_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_KM_7</masterLabel>
            <translation><!-- Glu_KM_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_KM_8</masterLabel>
            <translation><!-- Glu_KM_8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KM_1</masterLabel>
            <translation><!-- Monopril_KM_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KM_2</masterLabel>
            <translation><!-- Monopril_KM_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KM_3</masterLabel>
            <translation><!-- Monopril_KM_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KM_4</masterLabel>
            <translation><!-- Monopril_KM_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KM_5</masterLabel>
            <translation><!-- Monopril_KM_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KM_6</masterLabel>
            <translation><!-- Monopril_KM_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KM_7</masterLabel>
            <translation><!-- Monopril_KM_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KM_8</masterLabel>
            <translation><!-- Monopril_KM_8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No Value</masterLabel>
            <translation><!-- No Value --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KM_1</masterLabel>
            <translation><!-- Onglyza_KM_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KM_2</masterLabel>
            <translation><!-- Onglyza_KM_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KM_3</masterLabel>
            <translation><!-- Onglyza_KM_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KM_4</masterLabel>
            <translation><!-- Onglyza_KM_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KM_5</masterLabel>
            <translation><!-- Onglyza_KM_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KM_6</masterLabel>
            <translation><!-- Onglyza_KM_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KM_7</masterLabel>
            <translation><!-- Onglyza_KM_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KM_8</masterLabel>
            <translation><!-- Onglyza_KM_8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_1</masterLabel>
            <translation><!-- Paraplatin_KM_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_10</masterLabel>
            <translation><!-- Paraplatin_KM_10 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_2</masterLabel>
            <translation><!-- Paraplatin_KM_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_3</masterLabel>
            <translation><!-- Paraplatin_KM_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_4</masterLabel>
            <translation><!-- Paraplatin_KM_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_5</masterLabel>
            <translation><!-- Paraplatin_KM_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_6</masterLabel>
            <translation><!-- Paraplatin_KM_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_7</masterLabel>
            <translation><!-- Paraplatin_KM_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_8</masterLabel>
            <translation><!-- Paraplatin_KM_8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_9</masterLabel>
            <translation><!-- Paraplatin_KM_9 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL_KM_1</masterLabel>
            <translation><!-- SPRYCEL_KM_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL_KM_2</masterLabel>
            <translation><!-- SPRYCEL_KM_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL_KM_3</masterLabel>
            <translation><!-- SPRYCEL_KM_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL_KM_4</masterLabel>
            <translation><!-- SPRYCEL_KM_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_1</masterLabel>
            <translation><!-- Taxol_KM_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_2</masterLabel>
            <translation><!-- Taxol_KM_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_3</masterLabel>
            <translation><!-- Taxol_KM_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_4</masterLabel>
            <translation><!-- Taxol_KM_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_5</masterLabel>
            <translation><!-- Taxol_KM_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_6</masterLabel>
            <translation><!-- Taxol_KM_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_7</masterLabel>
            <translation><!-- Taxol_KM_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_8</masterLabel>
            <translation><!-- Taxol_KM_8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_9</masterLabel>
            <translation><!-- Taxol_KM_9 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_KM_1</masterLabel>
            <translation><!-- Theragran_G_KM_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_KM_2</masterLabel>
            <translation><!-- Theragran_G_KM_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_KM_3</masterLabel>
            <translation><!-- Theragran_G_KM_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_KM_4</masterLabel>
            <translation><!-- Theragran_G_KM_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_KM_5</masterLabel>
            <translation><!-- Theragran_G_KM_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_KM_6</masterLabel>
            <translation><!-- Theragran_G_KM_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_KM_7</masterLabel>
            <translation><!-- Theragran_G_KM_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_JR_KM_1</masterLabel>
            <translation><!-- Theragran_JR_KM_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_JR_KM_2</masterLabel>
            <translation><!-- Theragran_JR_KM_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VB_Complex_KM_1</masterLabel>
            <translation><!-- VB_Complex_KM_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VB_Complex_KM_2</masterLabel>
            <translation><!-- VB_Complex_KM_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VB_Complex_KM_3</masterLabel>
            <translation><!-- VB_Complex_KM_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VB_Complex_KM_4</masterLabel>
            <translation><!-- VB_Complex_KM_4 --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Key Topic --></label>
        <name>Key_Topics_BMS_EMEA__c</name>
        <picklistValues>
            <masterLabel>Brand&apos;s key messages</masterLabel>
            <translation><!-- Brand&apos;s key messages --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Brand&apos;s perception</masterLabel>
            <translation><!-- Brand&apos;s perception --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trials</masterLabel>
            <translation><!-- Clinical Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Company&apos;s perception</masterLabel>
            <translation><!-- Company&apos;s perception --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Compassionate Use Program</masterLabel>
            <translation><!-- Compassionate Use Program --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Compound-related question</masterLabel>
            <translation><!-- Compound-related question --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Congress</masterLabel>
            <translation><!-- Congress --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discussion on 3rd party tactics and sponsorship</masterLabel>
            <translation><!-- Discussion on 3rd party tactics and sponsorship --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Disease Area / Therapy Area Discussion</masterLabel>
            <translation><!-- Disease Area / Therapy Area Discussion --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Grants</masterLabel>
            <translation><!-- Grants --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Guidelines &amp; Therapeutic protocols on specific Disease</masterLabel>
            <translation><!-- Guidelines &amp; Therapeutic protocols on specific Disease --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IST&apos;s</masterLabel>
            <translation><!-- IST&apos;s --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Interventional Studies</masterLabel>
            <translation><!-- Interventional Studies --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Publications</masterLabel>
            <translation><!-- Publications --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Surveys</masterLabel>
            <translation><!-- Surveys --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- MSL Type --></label>
        <name>MSL_Type_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Material --></label>
        <name>Material_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>CN_PM1405</masterLabel>
            <translation><!-- CN_PM1405 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1406</masterLabel>
            <translation><!-- CN_PM1406 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1408</masterLabel>
            <translation><!-- CN_PM1408 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1412</masterLabel>
            <translation><!-- CN_PM1412 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1413</masterLabel>
            <translation><!-- CN_PM1413 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1416</masterLabel>
            <translation><!-- CN_PM1416 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1423</masterLabel>
            <translation><!-- CN_PM1423 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1424</masterLabel>
            <translation><!-- CN_PM1424 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1425</masterLabel>
            <translation><!-- CN_PM1425 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1430</masterLabel>
            <translation><!-- CN_PM1430 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA: Glucophage protect you all the time</masterLabel>
            <translation><!-- DA: Glucophage protect you all the time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA:Glucophage is the only initial therapy In new diagnosed T2DM patient</masterLabel>
            <translation><!-- DA:Glucophage is the only initial therapy In new diagnosed T2DM patient --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA:Optimal dosage (2000mg / day) achieve best hypoglycemic effect and cardiovascular benefit</masterLabel>
            <translation><!-- DA:Optimal dosage (2000mg / day) achieve best hypoglycemic effect and cardiovascular benefit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DELETE</masterLabel>
            <translation><!-- DELETE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_1_1</masterLabel>
            <translation><!-- Eliquis_MT_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_1_2</masterLabel>
            <translation><!-- Eliquis_MT_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_2_1</masterLabel>
            <translation><!-- Eliquis_MT_1_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_2_2</masterLabel>
            <translation><!-- Eliquis_MT_1_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_2_3</masterLabel>
            <translation><!-- Eliquis_MT_1_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_3_1</masterLabel>
            <translation><!-- Eliquis_MT_1_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_3_2</masterLabel>
            <translation><!-- Eliquis_MT_1_3_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_3_3</masterLabel>
            <translation><!-- Eliquis_MT_1_3_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_4_1</masterLabel>
            <translation><!-- Eliquis_MT_1_4_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_Achieved</masterLabel>
            <translation><!-- Glu_MT_Achieved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_1_1</masterLabel>
            <translation><!-- Monopril_MT_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_2_1</masterLabel>
            <translation><!-- Monopril_MT_1_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_2_2</masterLabel>
            <translation><!-- Monopril_MT_1_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_2_3</masterLabel>
            <translation><!-- Monopril_MT_1_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_2_4</masterLabel>
            <translation><!-- Monopril_MT_1_2_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_2_5</masterLabel>
            <translation><!-- Monopril_MT_1_2_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_2_6</masterLabel>
            <translation><!-- Monopril_MT_1_2_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_3_1</masterLabel>
            <translation><!-- Monopril_MT_1_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_3_3</masterLabel>
            <translation><!-- Monopril_MT_1_3_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_3_4</masterLabel>
            <translation><!-- Monopril_MT_1_3_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_3_5</masterLabel>
            <translation><!-- Monopril_MT_1_3_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_3_6</masterLabel>
            <translation><!-- Monopril_MT_1_3_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_3_7</masterLabel>
            <translation><!-- Monopril_MT_1_3_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_3_8</masterLabel>
            <translation><!-- Monopril_MT_1_3_8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_2_2_3</masterLabel>
            <translation><!-- Monopril_MT_2_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_2_2_5</masterLabel>
            <translation><!-- Monopril_MT_2_2_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_2_2_6</masterLabel>
            <translation><!-- Monopril_MT_2_2_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_2_3_1</masterLabel>
            <translation><!-- Monopril_MT_2_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_3_2_1</masterLabel>
            <translation><!-- Monopril_MT_3_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_3_2_3</masterLabel>
            <translation><!-- Monopril_MT_3_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_3_2_4</masterLabel>
            <translation><!-- Monopril_MT_3_2_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_3_2_5</masterLabel>
            <translation><!-- Monopril_MT_3_2_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_3_3_1</masterLabel>
            <translation><!-- Monopril_MT_3_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_3_3_2</masterLabel>
            <translation><!-- Monopril_MT_3_3_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_4_2_1</masterLabel>
            <translation><!-- Monopril_MT_4_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_4_2_2</masterLabel>
            <translation><!-- Monopril_MT_4_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_4_2_3</masterLabel>
            <translation><!-- Monopril_MT_4_2_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_4_2_4</masterLabel>
            <translation><!-- Monopril_MT_4_2_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_4_2_5</masterLabel>
            <translation><!-- Monopril_MT_4_2_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_4_3_1</masterLabel>
            <translation><!-- Monopril_MT_4_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_4_3_6</masterLabel>
            <translation><!-- Monopril_MT_4_3_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_Achlved</masterLabel>
            <translation><!-- Monopril_MT_Achlved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_MT_1_1_1</masterLabel>
            <translation><!-- Onglyza_MT_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_MT_1_1_2</masterLabel>
            <translation><!-- Onglyza_MT_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_MT_1_1_3</masterLabel>
            <translation><!-- Onglyza_MT_1_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_MT_1_3_3</masterLabel>
            <translation><!-- Onglyza_MT_1_3_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_1_1_1</masterLabel>
            <translation><!-- Paraplatin_MT_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_1_1_2</masterLabel>
            <translation><!-- Paraplatin_MT_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_1_1_3</masterLabel>
            <translation><!-- Paraplatin_MT_1_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_1_1_4</masterLabel>
            <translation><!-- Paraplatin_MT_1_1_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_1_2_1</masterLabel>
            <translation><!-- Paraplatin_MT_1_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_2_1_1</masterLabel>
            <translation><!-- Paraplatin_MT_2_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_2_1_2</masterLabel>
            <translation><!-- Paraplatin_MT_2_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_2_1_3</masterLabel>
            <translation><!-- Paraplatin_MT_2_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_2_2_1</masterLabel>
            <translation><!-- Paraplatin_MT_2_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_2_2_2</masterLabel>
            <translation><!-- Paraplatin_MT_2_2_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Slides:Global and domestic Diabetes Guideline</masterLabel>
            <translation><!-- Slides:Global and domestic Diabetes Guideline --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Slides:Gold standard of Metformin</masterLabel>
            <translation><!-- Slides:Gold standard of Metformin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Slides:Which can provide CV protection for T2DM patients.</masterLabel>
            <translation><!-- Slides:Which can provide CV protection for T2DM patients. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_1_1_1</masterLabel>
            <translation><!-- Taxol_MT_1_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_1_1_2</masterLabel>
            <translation><!-- Taxol_MT_1_1_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_1_1_3</masterLabel>
            <translation><!-- Taxol_MT_1_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_1_1_4</masterLabel>
            <translation><!-- Taxol_MT_1_1_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_1_3_1</masterLabel>
            <translation><!-- Taxol_MT_1_3_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_2_1_1</masterLabel>
            <translation><!-- Taxol_MT_2_1_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_2_1_3</masterLabel>
            <translation><!-- Taxol_MT_2_1_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_2_1_4</masterLabel>
            <translation><!-- Taxol_MT_2_1_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_2_2_1</masterLabel>
            <translation><!-- Taxol_MT_2_2_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_2_2_5</masterLabel>
            <translation><!-- Taxol_MT_2_2_5 --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Material OTC --></label>
        <name>Material_OTC_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>Ang_MT_1</masterLabel>
            <translation><!-- Ang_MT_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ang_MT_2</masterLabel>
            <translation><!-- Ang_MT_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ang_MT_3</masterLabel>
            <translation><!-- Ang_MT_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ang_MT_4</masterLabel>
            <translation><!-- Ang_MT_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BC_MT_1</masterLabel>
            <translation><!-- BC_MT_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BC_MT_2</masterLabel>
            <translation><!-- BC_MT_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BC_MT_3</masterLabel>
            <translation><!-- BC_MT_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BP_MT_1</masterLabel>
            <translation><!-- BP_MT_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BP_MT_2</masterLabel>
            <translation><!-- BP_MT_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BP_MT_3</masterLabel>
            <translation><!-- BP_MT_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BP_MT_4</masterLabel>
            <translation><!-- BP_MT_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Bco_MT_1</masterLabel>
            <translation><!-- Bco_MT_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Bco_MT_2</masterLabel>
            <translation><!-- Bco_MT_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Bco_MT_3</masterLabel>
            <translation><!-- Bco_MT_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Bco_MT_4</masterLabel>
            <translation><!-- Bco_MT_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA_MT_1</masterLabel>
            <translation><!-- DA_MT_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA_MT_2</masterLabel>
            <translation><!-- DA_MT_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA_MT_3</masterLabel>
            <translation><!-- DA_MT_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA_MT_4</masterLabel>
            <translation><!-- DA_MT_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA_MT_5</masterLabel>
            <translation><!-- DA_MT_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA_MT_6</masterLabel>
            <translation><!-- DA_MT_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA_MT_7</masterLabel>
            <translation><!-- DA_MT_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DELETE</masterLabel>
            <translation><!-- DELETE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DN_MT_1</masterLabel>
            <translation><!-- DN_MT_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DN_MT_2</masterLabel>
            <translation><!-- DN_MT_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DN_MT_3</masterLabel>
            <translation><!-- DN_MT_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DN_MT_4</masterLabel>
            <translation><!-- DN_MT_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DN_MT_5</masterLabel>
            <translation><!-- DN_MT_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1</masterLabel>
            <translation><!-- Eliquis_MT_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_2</masterLabel>
            <translation><!-- Eliquis_MT_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_3</masterLabel>
            <translation><!-- Eliquis_MT_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_1</masterLabel>
            <translation><!-- Glu_MT_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_2</masterLabel>
            <translation><!-- Glu_MT_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_3</masterLabel>
            <translation><!-- Glu_MT_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_4</masterLabel>
            <translation><!-- Glu_MT_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_5</masterLabel>
            <translation><!-- Glu_MT_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_6</masterLabel>
            <translation><!-- Glu_MT_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_7</masterLabel>
            <translation><!-- Glu_MT_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_8</masterLabel>
            <translation><!-- Glu_MT_8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_9</masterLabel>
            <translation><!-- Glu_MT_9 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1</masterLabel>
            <translation><!-- Monopril_MT_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_2</masterLabel>
            <translation><!-- Monopril_MT_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_3</masterLabel>
            <translation><!-- Monopril_MT_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No Value</masterLabel>
            <translation><!-- No Value --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_1</masterLabel>
            <translation><!-- Paraplatin_MT_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_2</masterLabel>
            <translation><!-- Paraplatin_MT_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_3</masterLabel>
            <translation><!-- Paraplatin_MT_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_4</masterLabel>
            <translation><!-- Paraplatin_MT_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_5</masterLabel>
            <translation><!-- Paraplatin_MT_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_6</masterLabel>
            <translation><!-- Paraplatin_MT_6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_7</masterLabel>
            <translation><!-- Paraplatin_MT_7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_8</masterLabel>
            <translation><!-- Paraplatin_MT_8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_9</masterLabel>
            <translation><!-- Paraplatin_MT_9 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TG_MT_1</masterLabel>
            <translation><!-- TG_MT_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TG_MT_2</masterLabel>
            <translation><!-- TG_MT_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TG_MT_3</masterLabel>
            <translation><!-- TG_MT_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TG_MT_4</masterLabel>
            <translation><!-- TG_MT_4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TG_MT_5</masterLabel>
            <translation><!-- TG_MT_5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TJD_MT_1</masterLabel>
            <translation><!-- TJD_MT_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TJD_MT_2</masterLabel>
            <translation><!-- TJD_MT_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TJD_MT_3</masterLabel>
            <translation><!-- TJD_MT_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_1</masterLabel>
            <translation><!-- Taxol_MT_1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_2</masterLabel>
            <translation><!-- Taxol_MT_2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_3</masterLabel>
            <translation><!-- Taxol_MT_3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_4</masterLabel>
            <translation><!-- Taxol_MT_4 --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Med Plan Alignment: Communication Topic --></label>
        <name>Med_Plan_Communication_Topic_BMS__c</name>
        <relationshipLabel><!-- Interaction Discussions --></relationshipLabel>
    </fields>
    <fields>
        <label><!-- Medical Communication Topic --></label>
        <name>Medical_Communication_Topic_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>1st line Dasatanib Clinical Trials</masterLabel>
            <translation><!-- 1st line Dasatanib Clinical Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>2013 Chinese CML treatment guideline</masterLabel>
            <translation><!-- 2013 Chinese CML treatment guideline --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AMPLE Study</masterLabel>
            <translation><!-- AMPLE Study --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AMPLIFY</masterLabel>
            <translation><!-- AMPLIFY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>APPRAISE-2</masterLabel>
            <translation><!-- APPRAISE-2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ARISTOTLE</masterLabel>
            <translation><!-- ARISTOTLE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ARISTOTLE &amp; AVERROES (including subgroup results)</masterLabel>
            <translation><!-- ARISTOTLE &amp; AVERROES (including subgroup results) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVERROES</masterLabel>
            <translation><!-- AVERROES --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Additional Benefits beyond glycemic control (weight loss, and reduction in SBP)</masterLabel>
            <translation><!-- Additional Benefits beyond glycemic control (weight loss, and reduction in SBP) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Advancing LT Patient care and treatment interruption in patients with Stable CMR &quot;Funcitonal Cure&quot;</masterLabel>
            <translation><!-- Advancing LT Patient care and treatment interruption in patients with Stable CMR &quot;Funcitonal Cure&quot; --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Advancing long-term patient care and treatment interruption in patients with stable CMR/”functional cure”</masterLabel>
            <translation><!-- Advancing long-term patient care and treatment interruption in patients with stable CMR/”functional cure” --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Adverse Event Management</masterLabel>
            <translation><!-- Adverse Event Management --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Adverse event management in CML</masterLabel>
            <translation><!-- Adverse event management in CML --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Amplify and Amplify EXT</masterLabel>
            <translation><!-- Amplify and Amplify EXT --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Apixaban Timing of administration: 12-24 hrs post surgery fits in hospital pattern of care</masterLabel>
            <translation><!-- Apixaban Timing of administration: 12-24 hrs post surgery fits in hospital pattern of care --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Apixabans PK Profile with limited renal elimination</masterLabel>
            <translation><!-- Apixabans PK Profile with limited renal elimination --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS HCV Clinical Trials</masterLabel>
            <translation><!-- BMS HCV Clinical Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Burden of Atrial Fibrilation and Stroke in India</masterLabel>
            <translation><!-- Burden of Atrial Fibrilation and Stroke in India --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Burden of T2D, CV risk factors, complications and CV outcomes</masterLabel>
            <translation><!-- Burden of T2D, CV risk factors, complications and CV outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Burden of T2D: CV Risk factors, complicaitons and CV outcomes</masterLabel>
            <translation><!-- Burden of T2D: CV Risk factors, complicaitons and CV outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Catalyze changes in the treatment paradigm focusing on a Patient Centic approach</masterLabel>
            <translation><!-- Catalyze changes in the treatment paradigm focusing on a Patient Centic approach --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Efficacy and Safety of Dasatanib in CML</masterLabel>
            <translation><!-- Clinical Efficacy and Safety of Dasatanib in CML --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Efficacy and Safety of Exenatide</masterLabel>
            <translation><!-- Clinical Efficacy and Safety of Exenatide --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Profile of Saxagliptin</masterLabel>
            <translation><!-- Clinical Profile of Saxagliptin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Co-morbidities in Atrial Fibrilation</masterLabel>
            <translation><!-- Co-morbidities in Atrial Fibrilation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate key data of SC Abatacept in RA management</masterLabel>
            <translation><!-- Communicate key data of SC Abatacept in RA management --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate the commitment of AZ/BMS Alliance to Med Education and Clinical Research in T2D</masterLabel>
            <translation><!-- Communicate the commitment of AZ/BMS Alliance to Med Education and Clinical Research in T2D --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DAPA Monotherapy Trial Data</masterLabel>
            <translation><!-- DAPA Monotherapy Trial Data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DAPA in Combination with Insulin</masterLabel>
            <translation><!-- DAPA in Combination with Insulin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DAPA in Combination with other oral glucose?lowering medicinal products Trial Data</masterLabel>
            <translation><!-- DAPA in Combination with other oral glucose?lowering medicinal products Trial Data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss Abatacepts response kinetics, short term and LT efficacy, comparative efficacy to other biologics and safety (Clin trials and real-life)</masterLabel>
            <translation><!-- Discuss Abatacepts response kinetics, short term and LT efficacy, comparative efficacy to other biologics and safety (Clin trials and real-life) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss Baraclude long-term efficacy, resistance, safety in CHB na?ve patients and decompensated cirrhosis patients.</masterLabel>
            <translation><!-- Discuss Baraclude long-term efficacy, resistance, safety in CHB na?ve patients and decompensated cirrhosis patients. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss Baraclude value position and high pharmaceutical technology in CHB long-term patient management.</masterLabel>
            <translation><!-- Discuss Baraclude value position and high pharmaceutical technology in CHB long-term patient management. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss drug resistance and potential long-term impact on future treatment options and resistance management based on 2013 Chinese resistance consensus.</masterLabel>
            <translation><!-- Discuss drug resistance and potential long-term impact on future treatment options and resistance management based on 2013 Chinese resistance consensus. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss long term safety of NUC treatment, highlighting long-term safety of Nucleotide monotherapy and combination therapy.</masterLabel>
            <translation><!-- Discuss long term safety of NUC treatment, highlighting long-term safety of Nucleotide monotherapy and combination therapy. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss the improvement of clinical outcomes during long-term antiviral treatment.</masterLabel>
            <translation><!-- Discuss the improvement of clinical outcomes during long-term antiviral treatment. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss the updated knowledge in disease area and guidelines, highlighting the importance of treating na?ve patient with potent and high genetic barrier NUCs.</masterLabel>
            <translation><!-- Discuss the updated knowledge in disease area and guidelines, highlighting the importance of treating na?ve patient with potent and high genetic barrier NUCs. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss updated treatment guidelines (2012 ACR) highlighting the use of Abatacept as 1st line biologic and target of low disease activity/remission</masterLabel>
            <translation><!-- Discuss updated treatment guidelines (2012 ACR) highlighting the use of Abatacept as 1st line biologic and target of low disease activity/remission --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discussing the unmet medical needs of Diabetes and its complications e.g. macrovascular complications</masterLabel>
            <translation><!-- Discussing the unmet medical needs of Diabetes and its complications e.g. macrovascular complications --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discussion on AF treatment Guidelines</masterLabel>
            <translation><!-- Discussion on AF treatment Guidelines --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ETV EVOLVE Study</masterLabel>
            <translation><!-- ETV EVOLVE Study --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ETV in CHB Patients undergoing chemo/immunosuppressive Therapy</masterLabel>
            <translation><!-- ETV in CHB Patients undergoing chemo/immunosuppressive Therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ETV in CHB Patients with HCC</masterLabel>
            <translation><!-- ETV in CHB Patients with HCC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ETV in CHB patients undergoing Liver Transplant</masterLabel>
            <translation><!-- ETV in CHB patients undergoing Liver Transplant --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate HCP on CHB disease, treatment guidelines and long term disease outcomes</masterLabel>
            <translation><!-- Educate HCP on CHB disease, treatment guidelines and long term disease outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate HCP on ETV in decompensated cirrhosis and OLT</masterLabel>
            <translation><!-- Educate HCP on ETV in decompensated cirrhosis and OLT --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate HCP on ETV’s long-term efficacy, resistance profile, histological improvement and renal and bone safety from clinical trials and real-life data</masterLabel>
            <translation><!-- Educate HCP on ETV’s long-term efficacy, resistance profile, histological improvement and renal and bone safety from clinical trials and real-life data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy and Safety of Abatacept in Lupus Nephritis</masterLabel>
            <translation><!-- Efficacy and Safety of Abatacept in Lupus Nephritis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy of Apixaban to prevent VTE/Death and major VTE vs enoxaparin 40 mg OD post THR/TKR Surgery</masterLabel>
            <translation><!-- Efficacy of Apixaban to prevent VTE/Death and major VTE vs enoxaparin 40 mg OD post THR/TKR Surgery --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy- Significant reduction of total VTE/Death and Major VTEs when compared to Enoxaparin 40 mg OD</masterLabel>
            <translation><!-- Efficacy- Significant reduction of total VTE/Death and Major VTEs when compared to Enoxaparin 40 mg OD --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Establishing saxagliptin’s efficacy in add-on to metformin through comprehensive control of HbA1c, FPG, PPG, as well as safety and long term durability</masterLabel>
            <translation><!-- Establishing saxagliptin’s efficacy in add-on to metformin through comprehensive control of HbA1c, FPG, PPG, as well as safety and long term durability --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Exanetides place in the treatment arnament for T2D</masterLabel>
            <translation><!-- Exanetides place in the treatment arnament for T2D --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Exenatide and Add-onto-Insulin; Add-onto-TZD</masterLabel>
            <translation><!-- Exenatide and Add-onto-Insulin; Add-onto-TZD --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Exenatide and TZD or Insulin add on studies</masterLabel>
            <translation><!-- Exenatide and TZD or Insulin add on studies --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Holistic apporach and benefits of multi-factorial intervention in T2D</masterLabel>
            <translation><!-- Holistic apporach and benefits of multi-factorial intervention in T2D --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Holistic approach and benefits of multifactorial intervention in T2D</masterLabel>
            <translation><!-- Holistic approach and benefits of multifactorial intervention in T2D --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Impact of early time to response and depth of response on LT patient outcomes</masterLabel>
            <translation><!-- Impact of early time to response and depth of response on LT patient outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Impact of early time to response and depth of response on long term patient outcomes (the benefit of “early switch”)</masterLabel>
            <translation><!-- Impact of early time to response and depth of response on long term patient outcomes (the benefit of “early switch”) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of CV Disease Prevention in T2D</masterLabel>
            <translation><!-- Importance of CV Disease Prevention in T2D --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of a Patient Centric approach in T2D treatment</masterLabel>
            <translation><!-- Importance of a Patient Centric approach in T2D treatment --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of adherence in CML</masterLabel>
            <translation><!-- Importance of adherence in CML --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Key Players in glucose balance including the role of the kidney</masterLabel>
            <translation><!-- Key Players in glucose balance including the role of the kidney --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Limitations of Current Therapies</masterLabel>
            <translation><!-- Limitations of Current Therapies --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Limitations of current insulin-dependent therapies. Progressive beta-cell failure and treatment failures</masterLabel>
            <translation><!-- Limitations of current insulin-dependent therapies. Progressive beta-cell failure and treatment failures --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Limitations of current insulin-dependent therapies: Progressive beta cell failure and treatment failure</masterLabel>
            <translation><!-- Limitations of current insulin-dependent therapies: Progressive beta cell failure and treatment failure --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Limited renal elimitation compared to other NOACs</masterLabel>
            <translation><!-- Limited renal elimitation compared to other NOACs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Long-Term Patient Management strategies for GI side effects</masterLabel>
            <translation><!-- Long-Term Patient Management strategies for GI side effects --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Long-term Impact of Exenatide on Beta cell function</masterLabel>
            <translation><!-- Long-term Impact of Exenatide on Beta cell function --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MOA of DAPA</masterLabel>
            <translation><!-- MOA of DAPA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MoA of SGLT2 inibitor: Global 066 renal splay</masterLabel>
            <translation><!-- MoA of SGLT2 inibitor: Global 066 renal splay --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monotherapy: Global 013/ China 054</masterLabel>
            <translation><!-- Monotherapy: Global 013/ China 054 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Option1</masterLabel>
            <translation><!-- Option1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Option2</masterLabel>
            <translation><!-- Option2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Option3</masterLabel>
            <translation><!-- Option3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Option4</masterLabel>
            <translation><!-- Option4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Option5</masterLabel>
            <translation><!-- Option5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other CV Clinical Trials</masterLabel>
            <translation><!-- Other CV Clinical Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other Dasatanib Clinical Trials</masterLabel>
            <translation><!-- Other Dasatanib Clinical Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other Metabolic Clinical Trials</masterLabel>
            <translation><!-- Other Metabolic Clinical Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other Oncology Clinical Trials</masterLabel>
            <translation><!-- Other Oncology Clinical Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other Virology Clinical Trials</masterLabel>
            <translation><!-- Other Virology Clinical Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ph+ALL treatment and Key Dasatanib trial data</masterLabel>
            <translation><!-- Ph+ALL treatment and Key Dasatanib trial data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ph+ALL treatmenta and Key Dasatanib trial data</masterLabel>
            <translation><!-- Ph+ALL treatmenta and Key Dasatanib trial data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Potential CV Protective role of Incretin based treatments</masterLabel>
            <translation><!-- Potential CV Protective role of Incretin based treatments --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Potential CV Protective role of Incretin class</masterLabel>
            <translation><!-- Potential CV Protective role of Incretin class --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Practical use of Apixaban in VTEP management</masterLabel>
            <translation><!-- Practical use of Apixaban in VTEP management --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Rationale for BID Dosing: Apixabans PK profile and Phase 2 study results</masterLabel>
            <translation><!-- Rationale for BID Dosing: Apixabans PK profile and Phase 2 study results --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Relative merits of glycaemic control</masterLabel>
            <translation><!-- Relative merits of glycaemic control --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPAF Disease Burden, the limitations of current therapies, Co-morbidities in AF,  &amp; economic impact of AF)</masterLabel>
            <translation><!-- SPAF Disease Burden, the limitations of current therapies, Co-morbidities in AF,  &amp; economic impact of AF) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety Retrospective CV Safety Data</masterLabel>
            <translation><!-- Safety Retrospective CV Safety Data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety of Apixaban in Post THR/TKR Surgery</masterLabel>
            <translation><!-- Safety of Apixaban in Post THR/TKR Surgery --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety, including renal safety, infections and cancer</masterLabel>
            <translation><!-- Safety, including renal safety, infections and cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety, including renal safety, infections and cancer: Pooled analysis</masterLabel>
            <translation><!-- Safety, including renal safety, infections and cancer: Pooled analysis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety- No increase in major or CRNM bleeds</masterLabel>
            <translation><!-- Safety- No increase in major or CRNM bleeds --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety: retrospective CV Safety data</masterLabel>
            <translation><!-- Safety: retrospective CV Safety data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Saxagliptin China Add-On Clinical Trials: Combination with Met, FDC, and add-onto-Insulin</masterLabel>
            <translation><!-- Saxagliptin China Add-On Clinical Trials: Combination with Met, FDC, and add-onto-Insulin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Saxagliptin Efficacy as either Monotherapy or in initial combination with Metformin</masterLabel>
            <translation><!-- Saxagliptin Efficacy as either Monotherapy or in initial combination with Metformin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Saxagliptin Global Add-On Clinical trials: SU, Insulin, TZDS</masterLabel>
            <translation><!-- Saxagliptin Global Add-On Clinical trials: SU, Insulin, TZDS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Saxagliptin as add-onto Insulin (057 study) or Saxagliptin Triple Therapy Study</masterLabel>
            <translation><!-- Saxagliptin as add-onto Insulin (057 study) or Saxagliptin Triple Therapy Study --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>The clinical efficacy and safety of Dasatinib in 2nd line of CML (034 data and local 160 data)</masterLabel>
            <translation><!-- The clinical efficacy and safety of Dasatinib in 2nd line of CML (034 data and local 160 data) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Timing of Apixaban administration after Surgery</masterLabel>
            <translation><!-- Timing of Apixaban administration after Surgery --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unmet Medical needs in T2D</masterLabel>
            <translation><!-- Unmet Medical needs in T2D --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unmet medical needs in T2D: Limitations of current treatment options including weight gain, hypoglycemia, CV Safety concerns.</masterLabel>
            <translation><!-- Unmet medical needs in T2D: Limitations of current treatment options including weight gain, hypoglycemia, CV Safety concerns. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VTEP Disease Burden &amp; its undertreatment in China</masterLabel>
            <translation><!-- VTEP Disease Burden &amp; its undertreatment in China --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Medical Communication Topic --></label>
        <name>Medical_Communication_Topic_BMS_EMEA__c</name>
        <picklistValues>
            <masterLabel>AEs: Support medical education to ensure safe and appropriate use of Nivolumab monotherapy</masterLabel>
            <translation><!-- AEs: Support medical education to ensure safe and appropriate use of Nivolumab monotherapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Accelerate the understanding &amp; value of immuno-oncology in the treatment of  NSCLC and melanoma</masterLabel>
            <translation><!-- Accelerate the understanding &amp; value of immuno-oncology in the treatment of  NSCLC and melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Address suboptimal anticoagulation - Discuss limitations of VKA in relation to Apixaban</masterLabel>
            <translation><!-- Address suboptimal anticoagulation - Discuss limitations of VKA in relation to Apixaban --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Address undiagnosed/ untreated patients  and  discuss the health economic rationale of AF screening in high-risk patients</masterLabel>
            <translation><!-- Address undiagnosed/ untreated patients  and  discuss the health economic rationale of AF screening in high-risk patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Advancing long-term patient care and treatment interruption in patients with stable CMR/&quot;functional cure&quot;</masterLabel>
            <translation><!-- Advancing long-term patient care and treatment interruption in patients with stable CMR/&quot;functional cure&quot; --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Adverse events/Safety: Facilitate appropriate understanding of AE’s management with established guidelines and existing algorithm</masterLabel>
            <translation><!-- Adverse events/Safety: Facilitate appropriate understanding of AE’s management with established guidelines and existing algorithm --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Amplify / VTE treatment</masterLabel>
            <translation><!-- Amplify / VTE treatment --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Answer questions on  bleeding /reversal data and timelines of availability</masterLabel>
            <translation><!-- Answer questions on  bleeding /reversal data and timelines of availability --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Apixaban pharmacokinetic and pharmacodynamic properties</masterLabel>
            <translation><!-- Apixaban pharmacokinetic and pharmacodynamic properties --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriate communication on the clinical value of elotuzumab</masterLabel>
            <translation><!-- Appropriate communication on the clinical value of elotuzumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriate communication on the clinical value of elotuzumab (reactive)</masterLabel>
            <translation><!-- Appropriate communication on the clinical value of elotuzumab (reactive) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriate communication on the economic and societal value of immuno-oncology</masterLabel>
            <translation><!-- Appropriate communication on the economic and societal value of immuno-oncology --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriate education on SLAMF7 as a critical target in MM</masterLabel>
            <translation><!-- Appropriate education on SLAMF7 as a critical target in MM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriate education on SLAMF7 as an I-O target in MM and establish the role of I-O in MM</masterLabel>
            <translation><!-- Appropriate education on SLAMF7 as an I-O target in MM and establish the role of I-O in MM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriate education on the clinical data and the relevant place of therapy for Elotuzumab in RRMM</masterLabel>
            <translation><!-- Appropriate education on the clinical data and the relevant place of therapy for Elotuzumab in RRMM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriate education on the rationale and clinical value of further studying immuno-oncology in melanoma</masterLabel>
            <translation><!-- Appropriate education on the rationale and clinical value of further studying immuno-oncology in melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriately communicate on the clinical data for nivolumab in Hodgkin lymphoma</masterLabel>
            <translation><!-- Appropriately communicate on the clinical data for nivolumab in Hodgkin lymphoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriately communicate the clinical relevance of abatacept’s unique MoA to positively alter the course of RA in eRP RA patients</masterLabel>
            <translation><!-- Appropriately communicate the clinical relevance of abatacept’s unique MoA to positively alter the course of RA in eRP RA patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriately communicate time out of refrigeration data for Orencia</masterLabel>
            <translation><!-- Appropriately communicate time out of refrigeration data for Orencia --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriately discuss BMS commitment to rheumatology and immunoscience by highlighting the Orencia LCM program and the BMS immunoscience pipeline</masterLabel>
            <translation><!-- Appropriately discuss BMS commitment to rheumatology and immunoscience by highlighting the Orencia LCM program and the BMS immunoscience pipeline --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriately educate on rationale for I-O therapies in HL</masterLabel>
            <translation><!-- Appropriately educate on rationale for I-O therapies in HL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriately initiate or switch to aripiprazole in BD &amp; SCZ and acute and long term efficacy and tolerability of aripiprazole in adult and adolescent SCZ patients</masterLabel>
            <translation><!-- Appropriately initiate or switch to aripiprazole in BD &amp; SCZ and acute and long term efficacy and tolerability of aripiprazole in adult and adolescent SCZ patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Aripiprazole from the start of a mania episode in adult BD and maintaining treatment in the long term in monotherapy or in combination with a mood stabilizer</masterLabel>
            <translation><!-- Aripiprazole from the start of a mania episode in adult BD and maintaining treatment in the long term in monotherapy or in combination with a mood stabilizer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Aristotle sub-analysis</masterLabel>
            <translation><!-- Aristotle sub-analysis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Averroes sub-analysis</masterLabel>
            <translation><!-- Averroes sub-analysis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BID dosing</masterLabel>
            <translation><!-- BID dosing --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS/AZ diabetes product range</masterLabel>
            <translation><!-- BMS/AZ diabetes product range --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Based on clinical profile, apixaban is cost-effective vs all anti-coagulants (including costs per stroke/bleeds, QALYs, and QoL inputs)</masterLabel>
            <translation><!-- Based on clinical profile, apixaban is cost-effective vs all anti-coagulants (including costs per stroke/bleeds, QALYs, and QoL inputs) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Belatacept is the first-in-class selective co-stimulation blocker that prevents T-cell activation</masterLabel>
            <translation><!-- Belatacept is the first-in-class selective co-stimulation blocker that prevents T-cell activation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Belatacept profile on Application, PK/PD and TDM</masterLabel>
            <translation><!-- Belatacept profile on Application, PK/PD and TDM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Belatacept results in high patients and graft survival in kidney transplant recipients in relation to long term safety</masterLabel>
            <translation><!-- Belatacept results in high patients and graft survival in kidney transplant recipients in relation to long term safety --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Blood pressure effect</masterLabel>
            <translation><!-- Blood pressure effect --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CV research- Discussion of potential apixaban clinical research beyond NVAF &amp; VTEtx</masterLabel>
            <translation><!-- CV research- Discussion of potential apixaban clinical research beyond NVAF &amp; VTEtx --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Cardiovascular safety of Saxagliptin (SAVOR data)</masterLabel>
            <translation><!-- Cardiovascular safety of Saxagliptin (SAVOR data) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clarify Guidelines strongly limited usage of aspirin in SPAF, supported by data proven its limited benefits and share new option availability supported by direct comparison versus aspirin (AVERROES)</masterLabel>
            <translation><!-- Clarify Guidelines strongly limited usage of aspirin in SPAF, supported by data proven its limited benefits and share new option availability supported by direct comparison versus aspirin (AVERROES) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clarify VKA Limitations</masterLabel>
            <translation><!-- Clarify VKA Limitations --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clarify how Apixaban ongoing life cycle program is addressing critical unmet needs in AF and VTE, identify data gap and contribute to address clinical unmet  medical needs</masterLabel>
            <translation><!-- Clarify how Apixaban ongoing life cycle program is addressing critical unmet needs in AF and VTE, identify data gap and contribute to address clinical unmet  medical needs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trials - Discuss planned or ongoing company sponsored studies</masterLabel>
            <translation><!-- Clinical Trials - Discuss planned or ongoing company sponsored studies --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trials - Discuss potential or ongoing “on Strategy”  ISRs</masterLabel>
            <translation><!-- Clinical Trials - Discuss potential or ongoing “on Strategy”  ISRs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical profile of exenatide once weekly (QW)</masterLabel>
            <translation><!-- Clinical profile of exenatide once weekly (QW) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical profile of exenatide twice daily (BID)</masterLabel>
            <translation><!-- Clinical profile of exenatide twice daily (BID) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical profile of saxagliptin</masterLabel>
            <translation><!-- Clinical profile of saxagliptin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Combination Regimen: Communicate appropriately on Combination regimen data and BMS clinical trials program to answer unmet medical needs</masterLabel>
            <translation><!-- Combination Regimen: Communicate appropriately on Combination regimen data and BMS clinical trials program to answer unmet medical needs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Combination Regimen: Support medical exchange on Nivolumab plus Ipilimumab Combination Regimen patient benefit</masterLabel>
            <translation><!-- Combination Regimen: Support medical exchange on Nivolumab plus Ipilimumab Combination Regimen patient benefit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate Apixaban medical value story based on TLs needs</masterLabel>
            <translation><!-- Communicate Apixaban medical value story based on TLs needs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate Efficacy, safety and Tolerability of EFV regimens in naïve with focus on comparison of EFV vs. Rilpivirine in terms of viral failure and emergence of cross resistance</masterLabel>
            <translation><!-- Communicate Efficacy, safety and Tolerability of EFV regimens in naïve with focus on comparison of EFV vs. Rilpivirine in terms of viral failure and emergence of cross resistance --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate appropriate dosing, efficacy and safety of ATV powder in children</masterLabel>
            <translation><!-- Communicate appropriate dosing, efficacy and safety of ATV powder in children --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate clinical and RW data that identify complementary eRP patient characteristics and validate the incremental efficacy of abatacept in select other patient types</masterLabel>
            <translation><!-- Communicate clinical and RW data that identify complementary eRP patient characteristics and validate the incremental efficacy of abatacept in select other patient types --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate data from ALLY-1 showing the efficacy and safety of DCV combined with SOF in the peri-transplant setting</masterLabel>
            <translation><!-- Communicate data from ALLY-1 showing the efficacy and safety of DCV combined with SOF in the peri-transplant setting --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate role of PI-based tx for durable suppression w low rates of resistance</masterLabel>
            <translation><!-- Communicate role of PI-based tx for durable suppression w low rates of resistance --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate that DCV has been studied in various combinations with NS3, NS5B  inhibitors and pegIFN+RBV in Phase 1, 2, and 3 studies in GT-1, -4 patients with high unmet needs</masterLabel>
            <translation><!-- Communicate that DCV has been studied in various combinations with NS3, NS5B  inhibitors and pegIFN+RBV in Phase 1, 2, and 3 studies in GT-1, -4 patients with high unmet needs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate that DCV is a potent new NS5A replication complex inhibitor with a pan-genotypic profile against the hepatitis C virus</masterLabel>
            <translation><!-- Communicate that DCV is a potent new NS5A replication complex inhibitor with a pan-genotypic profile against the hepatitis C virus --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate the value of Orencia’s formulation versatility via the autoinjector (AI) launch and availability of pediatric SC data sets</masterLabel>
            <translation><!-- Communicate the value of Orencia’s formulation versatility via the autoinjector (AI) launch and availability of pediatric SC data sets --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate through scientific exchange on efficacy and safety data for nivolumab as a treatment option for mRCC therapy</masterLabel>
            <translation><!-- Communicate through scientific exchange on efficacy and safety data for nivolumab as a treatment option for mRCC therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Core Orencia Messages and Clinical Data: MOA, Onset of action, ST &amp; LT Efficacy, breaking aTNF cycling,structural demage (XR, MRI, PDUS results), safety</masterLabel>
            <translation><!-- Core Orencia Messages and Clinical Data: MOA, Onset of action, ST &amp; LT Efficacy, breaking aTNF cycling,structural demage (XR, MRI, PDUS results), safety --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Core component of CML therapy</masterLabel>
            <translation><!-- Core component of CML therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Dasatinib provides value to patients by effectively targeting the disease, reducing risk of early progression, providing early deep responses and a predictable less bothersome tolerability profile with long term follow-up</masterLabel>
            <translation><!-- Dasatinib provides value to patients by effectively targeting the disease, reducing risk of early progression, providing early deep responses and a predictable less bothersome tolerability profile with long term follow-up --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Demonstrate  why ASA use is inappropriate</masterLabel>
            <translation><!-- Demonstrate  why ASA use is inappropriate --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Demonstrate BMS&apos; commitment to rheumatology and immunoscience by highlighting the LCM and pipeline</masterLabel>
            <translation><!-- Demonstrate BMS&apos; commitment to rheumatology and immunoscience by highlighting the LCM and pipeline --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Differentiate  Apixaban from the other oral anticoagulants</masterLabel>
            <translation><!-- Differentiate  Apixaban from the other oral anticoagulants --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Differentiate ATV vs DRV based on PK &amp; durable suppression in many ARV strategies</masterLabel>
            <translation><!-- Differentiate ATV vs DRV based on PK &amp; durable suppression in many ARV strategies --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Differentiate Apixaban vs other OACs</masterLabel>
            <translation><!-- Differentiate Apixaban vs other OACs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss CA209-026 lung data presented at ESMO 2016</masterLabel>
            <translation><!-- Discuss CA209-026 lung data presented at ESMO 2016 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss areas of unmet medical need in Lupus Nephritis</masterLabel>
            <translation><!-- Discuss areas of unmet medical need in Lupus Nephritis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss data from studies 040 and ALLY-3 showing the efficacy and safety of DCV combined with SOF in genotype 3 patients</masterLabel>
            <translation><!-- Discuss data from studies 040 and ALLY-3 showing the efficacy and safety of DCV combined with SOF in genotype 3 patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss evidence which supports positioning of Apixaban on Clinical Guidelines</masterLabel>
            <translation><!-- Discuss evidence which supports positioning of Apixaban on Clinical Guidelines --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss resistance profile of DCV</masterLabel>
            <translation><!-- Discuss resistance profile of DCV --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss the burden of HCV infection</masterLabel>
            <translation><!-- Discuss the burden of HCV infection --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss the challenges around HIV/HCV co-infection</masterLabel>
            <translation><!-- Discuss the challenges around HIV/HCV co-infection --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Disease awareness</masterLabel>
            <translation><!-- Disease awareness --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EHRA guidelines</masterLabel>
            <translation><!-- EHRA guidelines --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ESC guidelines</masterLabel>
            <translation><!-- ESC guidelines --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EULAR and treat to target recommendations</masterLabel>
            <translation><!-- EULAR and treat to target recommendations --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Early deep response to therapy is associated with longer progression free and overall survival</masterLabel>
            <translation><!-- Early deep response to therapy is associated with longer progression free and overall survival --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate HCPs on the appropriate use of Nivolumab in the treatment of lung cancer</masterLabel>
            <translation><!-- Educate HCPs on the appropriate use of Nivolumab in the treatment of lung cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate HCPs on the safety profile and appropriate use of Nivolumab in the treatment of lung cancer</masterLabel>
            <translation><!-- Educate HCPs on the safety profile and appropriate use of Nivolumab in the treatment of lung cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate around the particular burden of HCV Genotype 3 infection</masterLabel>
            <translation><!-- Educate around the particular burden of HCV Genotype 3 infection --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate market access stakeholders and specialty pharmacies on the value of DCV+SOF</masterLabel>
            <translation><!-- Educate market access stakeholders and specialty pharmacies on the value of DCV+SOF --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on GT-3 HCV disease state</masterLabel>
            <translation><!-- Educate on GT-3 HCV disease state --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on HIV/HCV coinfection  disease state</masterLabel>
            <translation><!-- Educate on HIV/HCV coinfection  disease state --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on advanced cirrhosis HCV disease state</masterLabel>
            <translation><!-- Educate on advanced cirrhosis HCV disease state --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on post liver transplant HCV disease state</masterLabel>
            <translation><!-- Educate on post liver transplant HCV disease state --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the DDI profile of DCV</masterLabel>
            <translation><!-- Educate on the DDI profile of DCV --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the appropriate dosing and safety profile of DCV</masterLabel>
            <translation><!-- Educate on the appropriate dosing and safety profile of DCV --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the efficacy and safety of DCV+SOF in GT-3 patients</masterLabel>
            <translation><!-- Educate on the efficacy and safety of DCV+SOF in GT-3 patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the efficacy and safety of DCV+SOF+RBV in GT-3 patients with compensated cirrhosis</masterLabel>
            <translation><!-- Educate on the efficacy and safety of DCV+SOF+RBV in GT-3 patients with compensated cirrhosis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the rationale and potential of immuno-oncology in cancer</masterLabel>
            <translation><!-- Educate on the rationale and potential of immuno-oncology in cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the rationale and value of research of immuno-oncology (I-O) agents as a treatment option in NSCLC and potentially also for SCLC</masterLabel>
            <translation><!-- Educate on the rationale and value of research of immuno-oncology (I-O) agents as a treatment option in NSCLC and potentially also for SCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the rationale and value of studying immuno-oncology (I-O) in lung cancer</masterLabel>
            <translation><!-- Educate on the rationale and value of studying immuno-oncology (I-O) in lung cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the role of PD-L1 as a potential biomarker for NSCLC</masterLabel>
            <translation><!-- Educate on the role of PD-L1 as a potential biomarker for NSCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the unmet medical need and guidelines on treatment of NSCLC and melanoma</masterLabel>
            <translation><!-- Educate on the unmet medical need and guidelines on treatment of NSCLC and melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the value to HCPs / patients / payers</masterLabel>
            <translation><!-- Educate on the value to HCPs / patients / payers --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate payor groups &amp; clinical market access stakeholders on ATV value</masterLabel>
            <translation><!-- Educate payor groups &amp; clinical market access stakeholders on ATV value --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Effects of exenatide on gastric emptying and central appetite control (BID)</masterLabel>
            <translation><!-- Effects of exenatide on gastric emptying and central appetite control (BID) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy and safety of DCV+SOF in HIV/HCV coinfection</masterLabel>
            <translation><!-- Efficacy and safety of DCV+SOF in HIV/HCV coinfection --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy and safety of DCV+SOF+RBV in advanced cirrhosis</masterLabel>
            <translation><!-- Efficacy and safety of DCV+SOF+RBV in advanced cirrhosis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy and safety of DCV+SOF+RBV post liver transplant</masterLabel>
            <translation><!-- Efficacy and safety of DCV+SOF+RBV post liver transplant --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy and safety of aripiprazole in the relevant patients</masterLabel>
            <translation><!-- Efficacy and safety of aripiprazole in the relevant patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy of apixaban to prevent VTE/death and major VTE vs enoxaparin 40 mg OD in THR and TKR surgery</masterLabel>
            <translation><!-- Efficacy of apixaban to prevent VTE/death and major VTE vs enoxaparin 40 mg OD in THR and TKR surgery --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy/safety profile: Apixaban demonstrated efficacy benefit, safety benefit and mortality benefit across a wide range of patients</masterLabel>
            <translation><!-- Efficacy/safety profile: Apixaban demonstrated efficacy benefit, safety benefit and mortality benefit across a wide range of patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Enhance awareness of abatacept’s safety profile</masterLabel>
            <translation><!-- Enhance awareness of abatacept’s safety profile --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Enhance the understanding &amp; value of immuno-oncology in the treatment of lung cancer</masterLabel>
            <translation><!-- Enhance the understanding &amp; value of immuno-oncology in the treatment of lung cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Enhance understanding of I-O in the treatment of metastatic melanoma</masterLabel>
            <translation><!-- Enhance understanding of I-O in the treatment of metastatic melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ensure payers /hospital awareness on apixaban value and appropriate use</masterLabel>
            <translation><!-- Ensure payers /hospital awareness on apixaban value and appropriate use --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Establish abatacept’s ability to achieve robust remission rates in early RA patients with potential to de-escalate or withdraw therapy</masterLabel>
            <translation><!-- Establish abatacept’s ability to achieve robust remission rates in early RA patients with potential to de-escalate or withdraw therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Establish the benefits of abatacept as an optimal choice for patients with early, rapidly progressing rheumatoid arthritis</masterLabel>
            <translation><!-- Establish the benefits of abatacept as an optimal choice for patients with early, rapidly progressing rheumatoid arthritis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Establish the benefits of first-line use of abatacept in biologic naïve and 1st -switch RA patients versus TNFi, TNF cycling and other biologic agents</masterLabel>
            <translation><!-- Establish the benefits of first-line use of abatacept in biologic naïve and 1st -switch RA patients versus TNFi, TNF cycling and other biologic agents --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Existing and future treatment guidelines in BD and data relevant to guideline development</masterLabel>
            <translation><!-- Existing and future treatment guidelines in BD and data relevant to guideline development --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Explain DCV’s safety and tolerability profile, with QD dosing, and a favorable DDI profile, making it an important component of therapeutic regimens for patients with high unmet needs</masterLabel>
            <translation><!-- Explain DCV’s safety and tolerability profile, with QD dosing, and a favorable DDI profile, making it an important component of therapeutic regimens for patients with high unmet needs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Explain how Apixaban RWD / HEOR complements the safety and efficacy demonstrated in  randomised controlled trials</masterLabel>
            <translation><!-- Explain how Apixaban RWD / HEOR complements the safety and efficacy demonstrated in  randomised controlled trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Favorable recommendations for DPPIV inhibitors vs SUs in the 2012 ADA/EASD position statement</masterLabel>
            <translation><!-- Favorable recommendations for DPPIV inhibitors vs SUs in the 2012 ADA/EASD position statement --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Favorable recommendations for GLP-1 agonists in the ADA/EASD position statement</masterLabel>
            <translation><!-- Favorable recommendations for GLP-1 agonists in the ADA/EASD position statement --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GU experience and knowledge: Leverage existing Nivolumab experience in RCC and BMS leadership in I-O in other indications</masterLabel>
            <translation><!-- GU experience and knowledge: Leverage existing Nivolumab experience in RCC and BMS leadership in I-O in other indications --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glycemic efficacy</masterLabel>
            <translation><!-- Glycemic efficacy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>H2H and AMPLE 1 and 2 y results</masterLabel>
            <translation><!-- H2H and AMPLE 1 and 2 y results --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCV Genotype Impact &amp; specific patient populations</masterLabel>
            <translation><!-- HCV Genotype Impact &amp; specific patient populations --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HEOR/Sustained value to patients and HCPs</masterLabel>
            <translation><!-- HEOR/Sustained value to patients and HCPs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Highlight current areas of unmet medical need in PsA and discuss how abatacept may address certain of these needs</masterLabel>
            <translation><!-- Highlight current areas of unmet medical need in PsA and discuss how abatacept may address certain of these needs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Highlight current areas of unmet medical need in PsA and discuss how abatacept may address certain of these needs in focused patient type, linking clinical outcomes to underlying pathology and MoA of abatacept</masterLabel>
            <translation><!-- Highlight current areas of unmet medical need in PsA and discuss how abatacept may address certain of these needs in focused patient type, linking clinical outcomes to underlying pathology and MoA of abatacept --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Highlight patient profiles that are particularly likely to benefit from abatacept therapy</masterLabel>
            <translation><!-- Highlight patient profiles that are particularly likely to benefit from abatacept therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IO Medical education: Support better understanding of I-O therapy rational and benefits as well as early identification and management of irAEs to ensure safe and appropriate use of these important new treatment option</masterLabel>
            <translation><!-- IO Medical education: Support better understanding of I-O therapy rational and benefits as well as early identification and management of irAEs to ensure safe and appropriate use of these important new treatment option --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IO concept: Educate HCP on the rationale for studying the Potential of Immuno-Oncology in Genitourinary Cancers</masterLabel>
            <translation><!-- IO concept: Educate HCP on the rationale for studying the Potential of Immuno-Oncology in Genitourinary Cancers --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IO for mRCC: Inform TL on evolving advances in treatment and communicate the clinical value of IO in mRCC</masterLabel>
            <translation><!-- IO for mRCC: Inform TL on evolving advances in treatment and communicate the clinical value of IO in mRCC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IO medical education: Support better understanding of IO therapy rational and benefits as well as early identification and management of irAEs to ensure safe and appropriate use of these important new treatment option</masterLabel>
            <translation><!-- IO medical education: Support better understanding of IO therapy rational and benefits as well as early identification and management of irAEs to ensure safe and appropriate use of these important new treatment option --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Impact of early time to response  and depth of response on long term patient outcomes</masterLabel>
            <translation><!-- Impact of early time to response  and depth of response on long term patient outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of Cardiovascular Disease in type 2 diabetes and a multidisciplinary management approach</masterLabel>
            <translation><!-- Importance of Cardiovascular Disease in type 2 diabetes and a multidisciplinary management approach --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of adherence in CML</masterLabel>
            <translation><!-- Importance of adherence in CML --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of continuing on therapy (adherence)</masterLabel>
            <translation><!-- Importance of continuing on therapy (adherence) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of patient preference and adherence in type 2 diabetes management (QW)</masterLabel>
            <translation><!-- Importance of patient preference and adherence in type 2 diabetes management (QW) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of patient-centric approach in diabetes treatment</masterLabel>
            <translation><!-- Importance of patient-centric approach in diabetes treatment --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of response to first line therapy</masterLabel>
            <translation><!-- Importance of response to first line therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Indication</masterLabel>
            <translation><!-- Indication --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Inform on guidelines on the treatment of lung cancer</masterLabel>
            <translation><!-- Inform on guidelines on the treatment of lung cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Inform on the on-going unmet medical needs in lung cancer</masterLabel>
            <translation><!-- Inform on the on-going unmet medical needs in lung cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Inform on the unmet medical need and guidelines on treatment of lung cancer</masterLabel>
            <translation><!-- Inform on the unmet medical need and guidelines on treatment of lung cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Inform on the unmet medical need and guidelines on treatment of metastatic melanoma</masterLabel>
            <translation><!-- Inform on the unmet medical need and guidelines on treatment of metastatic melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Inform on the unmet medical need despite recent and evolving advances in treatment</masterLabel>
            <translation><!-- Inform on the unmet medical need despite recent and evolving advances in treatment --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Inform on the unmet medical need in the treatment of Hodgkin Lymphoma</masterLabel>
            <translation><!-- Inform on the unmet medical need in the treatment of Hodgkin Lymphoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Inform on the unmet medical need in the treatment of multiple myeloma</masterLabel>
            <translation><!-- Inform on the unmet medical need in the treatment of multiple myeloma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ipi mono: Share durable, long-term survival benefit in pts with adv. Mel. and antitumor activity across pt subgroups. Ipi is associated with immune-mediated adverse reactions, but most were reversible in studies using established mgmt guidelines</masterLabel>
            <translation><!-- Ipi mono: Share durable, long-term survival benefit in pts with adv. Mel. and antitumor activity across pt subgroups. Ipi is associated with immune-mediated adverse reactions, but most were reversible in studies using established mgmt guidelines --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>LCM: Disseminate key scientific, clinical, and outcome–related data from the LCM space to enable a greater understanding of I-O for the advancement of scientific knowledge</masterLabel>
            <translation><!-- LCM: Disseminate key scientific, clinical, and outcome–related data from the LCM space to enable a greater understanding of I-O for the advancement of scientific knowledge --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Limitations of currently available immunosuppressive therapies, protocols and their impact on renal function, graft and Patient survival, acute rejection and the relationship of safety and LT outcome</masterLabel>
            <translation><!-- Limitations of currently available immunosuppressive therapies, protocols and their impact on renal function, graft and Patient survival, acute rejection and the relationship of safety and LT outcome --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Long-term Patient Outcomes</masterLabel>
            <translation><!-- Long-term Patient Outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Long-term Potency</masterLabel>
            <translation><!-- Long-term Potency --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Long-term safety</masterLabel>
            <translation><!-- Long-term safety --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MOA</masterLabel>
            <translation><!-- MOA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Medical Value message (HEOR): Orencia in real life, ACTION, ASCORE,local registries</masterLabel>
            <translation><!-- Medical Value message (HEOR): Orencia in real life, ACTION, ASCORE,local registries --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Misc - answer questions on MOA, DDI or general practical use  / disease or NOAC overview education</masterLabel>
            <translation><!-- Misc - answer questions on MOA, DDI or general practical use  / disease or NOAC overview education --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS5A-inhibition</masterLabel>
            <translation><!-- NS5A-inhibition --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nivo mono: Appropriately communicate data on OS benefit and durable response, across lines of therapies, melanoma tumor status, PDL-1 expression</masterLabel>
            <translation><!-- Nivo mono: Appropriately communicate data on OS benefit and durable response, across lines of therapies, melanoma tumor status, PDL-1 expression --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nivolumab 2nd line (025): Communicate the clinical value and patient benefit and safety profile of nivolumab</masterLabel>
            <translation><!-- Nivolumab 2nd line (025): Communicate the clinical value and patient benefit and safety profile of nivolumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nivolumab Mono in 2L: Communicate appropriately on data on OS, long term OS, ORR and quality of life benefit</masterLabel>
            <translation><!-- Nivolumab Mono in 2L: Communicate appropriately on data on OS, long term OS, ORR and quality of life benefit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nivolumab Mono in 2L: Raise awareness of current unmet medical need across the bladder cancer treatment continuum and appropriately communicate Nivolumab clinical trial program and existing data</masterLabel>
            <translation><!-- Nivolumab Mono in 2L: Raise awareness of current unmet medical need across the bladder cancer treatment continuum and appropriately communicate Nivolumab clinical trial program and existing data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ongoing Clinical Trials – LCM - Discuss planned or ongoing ACROPOLIS studies including Alliance sponsored, ISR research and  RISTA  programme. excluding study support</masterLabel>
            <translation><!-- Ongoing Clinical Trials – LCM - Discuss planned or ongoing ACROPOLIS studies including Alliance sponsored, ISR research and  RISTA  programme. excluding study support --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PK profile with limited renal elimination</masterLabel>
            <translation><!-- PK profile with limited renal elimination --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Potential effect of HBR on chronic inflammation and CV risk</masterLabel>
            <translation><!-- Potential effect of HBR on chronic inflammation and CV risk --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Practical use</masterLabel>
            <translation><!-- Practical use --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Practical use of Apixaban</masterLabel>
            <translation><!-- Practical use of Apixaban --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Practical use of ipilimumab</masterLabel>
            <translation><!-- Practical use of ipilimumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Provide education/support for patient care improvement</masterLabel>
            <translation><!-- Provide education/support for patient care improvement --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Provide guidance on the practical use of ipilimumab</masterLabel>
            <translation><!-- Provide guidance on the practical use of ipilimumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactively discuss potential future indications for abatacept (including Sjogren’s, GCA, Myositis) outlining areas of unmet medical need and how abatacept’s unique mode of action may be relevant to these conditions</masterLabel>
            <translation><!-- Reactively discuss potential future indications for abatacept (including Sjogren’s, GCA, Myositis) outlining areas of unmet medical need and how abatacept’s unique mode of action may be relevant to these conditions --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reinforce BMS commitment to Virology and leverage early HIV assets</masterLabel>
            <translation><!-- Reinforce BMS commitment to Virology and leverage early HIV assets --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reinforce rationale for maintaining ATV in clin &amp; virol suppressed pts</masterLabel>
            <translation><!-- Reinforce rationale for maintaining ATV in clin &amp; virol suppressed pts --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Relative merits of measures of glycaemic control</masterLabel>
            <translation><!-- Relative merits of measures of glycaemic control --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Respond to other unsolicited inquiries</masterLabel>
            <translation><!-- Respond to other unsolicited inquiries --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Respond to other unsolicited queries</masterLabel>
            <translation><!-- Respond to other unsolicited queries --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Respond to unsolicited inquiries</masterLabel>
            <translation><!-- Respond to unsolicited inquiries --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Respond to unsolicited queries on the dasatinib compound</masterLabel>
            <translation><!-- Respond to unsolicited queries on the dasatinib compound --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Respond to unsolicited queries on the dasatinib compound including but not limited to Ph+ALL</masterLabel>
            <translation><!-- Respond to unsolicited queries on the dasatinib compound including but not limited to Ph+ALL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Review data from ALLY-2 showing the efficacy and safety of DCV combined with SOF in HIV/HCV co-infected patients</masterLabel>
            <translation><!-- Review data from ALLY-2 showing the efficacy and safety of DCV combined with SOF in HIV/HCV co-infected patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Review the replication cycle of HCV and the essential role of NS5A in HCV replication and assembly that makes it a key target  for DAA therapy</masterLabel>
            <translation><!-- Review the replication cycle of HCV and the essential role of NS5A in HCV replication and assembly that makes it a key target  for DAA therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Review treatment challenges for peri-transplant patients</masterLabel>
            <translation><!-- Review treatment challenges for peri-transplant patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Role of ATV/r-based therapy in Women</masterLabel>
            <translation><!-- Role of ATV/r-based therapy in Women --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Role of ipilimumab in the treatment of metastatic melanoma</masterLabel>
            <translation><!-- Role of ipilimumab in the treatment of metastatic melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Role of ipilimumab in the treatment of pre-treated melanoma with a focus on the mode of action and the efficacy (Efficacy outcomes including the long term survival)</masterLabel>
            <translation><!-- Role of ipilimumab in the treatment of pre-treated melanoma with a focus on the mode of action and the efficacy (Efficacy outcomes including the long term survival) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safe and appropriate use of dasatinib</masterLabel>
            <translation><!-- Safe and appropriate use of dasatinib --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety and tolerability</masterLabel>
            <translation><!-- Safety and tolerability --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety of apixaban in post THR and TKR surgery</masterLabel>
            <translation><!-- Safety of apixaban in post THR and TKR surgery --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety profile and appropriate use of dasatinib</masterLabel>
            <translation><!-- Safety profile and appropriate use of dasatinib --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Share Warfarin limitations of use demonstrated in Real World data and leverage the efficacy and safety benefits of NOACs and Apixaban versus Warfarin for NVAF patients</masterLabel>
            <translation><!-- Share Warfarin limitations of use demonstrated in Real World data and leverage the efficacy and safety benefits of NOACs and Apixaban versus Warfarin for NVAF patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Subcutaneous Abatacept Clinical Program: Communication of Phase 3 SC Clinical Data</masterLabel>
            <translation><!-- Subcutaneous Abatacept Clinical Program: Communication of Phase 3 SC Clinical Data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Subgroups – Cancer</masterLabel>
            <translation><!-- Subgroups – Cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Subgroups – Dose reduction / appropriate dosing</masterLabel>
            <translation><!-- Subgroups – Dose reduction / appropriate dosing --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Support VTEtx launch, differentiate apixaban from standard of care and contribute to value proposition discussions</masterLabel>
            <translation><!-- Support VTEtx launch, differentiate apixaban from standard of care and contribute to value proposition discussions --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Support the differentiated apixaban profile</masterLabel>
            <translation><!-- Support the differentiated apixaban profile --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>The clinical efficacy and safety of dasatanib in CML providing practice informing information</masterLabel>
            <translation><!-- The clinical efficacy and safety of dasatanib in CML providing practice informing information --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Timing of administration after surgery</masterLabel>
            <translation><!-- Timing of administration after surgery --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Timing of administration perioperatively</masterLabel>
            <translation><!-- Timing of administration perioperatively --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Translate the clinical relevance of abatacept’s unique MoA to positively alter the course of RA</masterLabel>
            <translation><!-- Translate the clinical relevance of abatacept’s unique MoA to positively alter the course of RA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Treatment free remission (TFR) and cure are unmet needs for patients with CML</masterLabel>
            <translation><!-- Treatment free remission (TFR) and cure are unmet needs for patients with CML --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Treatment of metastatic melanoma within guidelines and unmet medical need for patients</masterLabel>
            <translation><!-- Treatment of metastatic melanoma within guidelines and unmet medical need for patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Treatment of other genotypes with DCV+SOF</masterLabel>
            <translation><!-- Treatment of other genotypes with DCV+SOF --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unmet Medical Need in HCV</masterLabel>
            <translation><!-- Unmet Medical Need in HCV --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unmet medical need and guidelines on treatment of metastatic melanoma</masterLabel>
            <translation><!-- Unmet medical need and guidelines on treatment of metastatic melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unmet medical needs in type 2 diabetes</masterLabel>
            <translation><!-- Unmet medical needs in type 2 diabetes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Use of ATV in new treatment strategies, with and in light of new agents</masterLabel>
            <translation><!-- Use of ATV in new treatment strategies, with and in light of new agents --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Use of PI/r in naïve and early switch pts, with focus on long-term efficacy, tolerability, safety, and convenience of ATV/r</masterLabel>
            <translation><!-- Use of PI/r in naïve and early switch pts, with focus on long-term efficacy, tolerability, safety, and convenience of ATV/r --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Value to HCPs / patients / payers</masterLabel>
            <translation><!-- Value to HCPs / patients / payers --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Warnings and cautions for use</masterLabel>
            <translation><!-- Warnings and cautions for use --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Weight loss</masterLabel>
            <translation><!-- Weight loss --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label>Tıbbi Vaka</label>
        <name>Medical_Event_vod__c</name>
        <relationshipLabel>Ziyaret Müzakereleri</relationshipLabel>
    </fields>
    <fields>
        <label><!-- Medical Plan Strategy --></label>
        <name>Medical_Plan_Strategy_BMS__c</name>
    </fields>
    <fields>
        <label>Mobil Kimlik</label>
        <name>Mobile_ID_vod__c</name>
    </fields>
    <fields>
        <label>Sonraki Ziyaret Hedefi</label>
        <name>Next_Call_Objective_BMS_EMEA__c</name>
        <picklistValues>
            <masterLabel>Awareness</masterLabel>
            <translation>Farkında</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Increased Understanding</masterLabel>
            <translation>Ürün Bilgisi Artan</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Integration / Extend</masterLabel>
            <translation>Entegrasyonu Artan</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Positive Attitude / Try</masterLabel>
            <translation>Olumlu / Deneyen</translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Overall Customer Feedback --></label>
        <name>Overall_Customer_Feedback_BMS_CA__c</name>
        <picklistValues>
            <masterLabel>Aware</masterLabel>
            <translation><!-- Aware --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Disengagement</masterLabel>
            <translation><!-- Disengagement --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Initiating</masterLabel>
            <translation><!-- Initiating --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>On Board</masterLabel>
            <translation><!-- On Board --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Studying</masterLabel>
            <translation><!-- Studying --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Uninterested</masterLabel>
            <translation><!-- Uninterested --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label>Özel Sipariş Kilidi</label>
        <name>Override_Lock_vod__c</name>
    </fields>
    <fields>
        <label><!-- Patient Type --></label>
        <name>Patient_Type_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>Advanced Ovarian Cancer</masterLabel>
            <translation><!-- Advanced Ovarian Cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Core Message</masterLabel>
            <translation><!-- Core Message --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DELETE</masterLabel>
            <translation><!-- DELETE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Defense Generic</masterLabel>
            <translation><!-- Defense Generic --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Early-stage Breast Cancer</masterLabel>
            <translation><!-- Early-stage Breast Cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glucose uncontrol with mono Met dosage 1500mg above T2DM patients</masterLabel>
            <translation><!-- Glucose uncontrol with mono Met dosage 1500mg above T2DM patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HTN with CHD</masterLabel>
            <translation><!-- HTN with CHD --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HTN with MI (NSTEMI/STEMI)</masterLabel>
            <translation><!-- HTN with MI (NSTEMI/STEMI) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HTN with UA/A-PCI</masterLabel>
            <translation><!-- HTN with UA/A-PCI --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Heart Failure</masterLabel>
            <translation><!-- Heart Failure --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>New T2DM patients</masterLabel>
            <translation><!-- New T2DM patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>New diagnosed T2DM patients</masterLabel>
            <translation><!-- New diagnosed T2DM patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>OC</masterLabel>
            <translation><!-- OC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SCLC</masterLabel>
            <translation><!-- SCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TKR patients</masterLabel>
            <translation><!-- TKR patients --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Pipeline / Other --></label>
        <name>Pipeline_Other_BMS_CA__c</name>
        <picklistValues>
            <masterLabel>11βHSD Inhibitors</masterLabel>
            <translation><!-- 11βHSD Inhibitors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ABILIFY® (aripiprazole)</masterLabel>
            <translation><!-- ABILIFY® (aripiprazole) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ATRIPLA® (efavirenz/emtricitabine/tenofovir disoproxil fumarate)</masterLabel>
            <translation><!-- ATRIPLA® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVALIDE® (irbesartan hydrochlorothiazide)</masterLabel>
            <translation><!-- AVALIDE® (irbesartan hydrochlorothiazide) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVAPRO® (irbesartan)</masterLabel>
            <translation><!-- AVAPRO® (irbesartan) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-CD28</masterLabel>
            <translation><!-- Anti-CD28 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-CD40L</masterLabel>
            <translation><!-- Anti-CD40L --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-CD70 ADC</masterLabel>
            <translation><!-- Anti-CD70 ADC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-CXCR4</masterLabel>
            <translation><!-- Anti-CXCR4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-IL31</masterLabel>
            <translation><!-- Anti-IL31 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-IL6</masterLabel>
            <translation><!-- Anti-IL6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-IP10</masterLabel>
            <translation><!-- Anti-IP10 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-KIR</masterLabel>
            <translation><!-- Anti-KIR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-LAG3</masterLabel>
            <translation><!-- Anti-LAG3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-PD-L1</masterLabel>
            <translation><!-- Anti-PD-L1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-PD1</masterLabel>
            <translation><!-- Anti-PD1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Asunaprevir (NS3 Inhibitor)</masterLabel>
            <translation><!-- Asunaprevir (NS3 Inhibitor) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Avagacestat (Gamma Secretase Inhibitor)</masterLabel>
            <translation><!-- Avagacestat (Gamma Secretase Inhibitor) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Aβ Modulator</masterLabel>
            <translation><!-- Aβ Modulator --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BARACLUDE® (entecavir)</masterLabel>
            <translation><!-- BARACLUDE® (entecavir) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BICNU® (carmustine)</masterLabel>
            <translation><!-- BICNU® (carmustine) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BUSPAR® (buspirone hydrochloride)</masterLabel>
            <translation><!-- BUSPAR® (buspirone hydrochloride) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Brivanib</masterLabel>
            <translation><!-- Brivanib --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CCR1 Antagonists</masterLabel>
            <translation><!-- CCR1 Antagonists --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CCR2 / 5</masterLabel>
            <translation><!-- CCR2 / 5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CEENU® (lomustine)</masterLabel>
            <translation><!-- CEENU® (lomustine) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CGRP Antagonist</masterLabel>
            <translation><!-- CGRP Antagonist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>COUMADIN® (warfarin sodium)</masterLabel>
            <translation><!-- COUMADIN® (warfarin sodium) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CVMet General</masterLabel>
            <translation><!-- CVMet General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DROXIA® (hydroxyurea)</masterLabel>
            <translation><!-- DROXIA® (hydroxyurea) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Daclatasvir (NS5A inhibitor)</masterLabel>
            <translation><!-- Daclatasvir (NS5A inhibitor) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EGFR/IGFR Tandem Adnectin</masterLabel>
            <translation><!-- EGFR/IGFR Tandem Adnectin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ERBITUX® (cetuximab)</masterLabel>
            <translation><!-- ERBITUX® (cetuximab) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ETOPOPHOS® (etoposide phosphate)</masterLabel>
            <translation><!-- ETOPOPHOS® (etoposide phosphate) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis® (apixaban)</masterLabel>
            <translation><!-- Eliquis® (apixaban) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Elotuzumab</masterLabel>
            <translation><!-- Elotuzumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>FGF21-PKE Adnectin</masterLabel>
            <translation><!-- FGF21-PKE Adnectin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>FORXIGA® (dapagliflozin)</masterLabel>
            <translation><!-- FORXIGA® (dapagliflozin) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GABA/Nicotinic Modulator</masterLabel>
            <translation><!-- GABA/Nicotinic Modulator --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GLUCOPHAGE® (metformin hydrochloride)</masterLabel>
            <translation><!-- GLUCOPHAGE® (metformin hydrochloride) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GPR119 Agonists</masterLabel>
            <translation><!-- GPR119 Agonists --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV Attachment Inhibitor</masterLabel>
            <translation><!-- HIV Attachment Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV General</masterLabel>
            <translation><!-- HIV General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV Maturation Inhibitor</masterLabel>
            <translation><!-- HIV Maturation Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HYDREA® (hydroxyurea)</masterLabel>
            <translation><!-- HYDREA® (hydroxyurea) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Hepatitis General</masterLabel>
            <translation><!-- Hepatitis General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IGF-1R Antagonist</masterLabel>
            <translation><!-- IGF-1R Antagonist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IKACh Inhibitors</masterLabel>
            <translation><!-- IKACh Inhibitors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IKur</masterLabel>
            <translation><!-- IKur --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IL-21</masterLabel>
            <translation><!-- IL-21 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IL-23 Adnectin</masterLabel>
            <translation><!-- IL-23 Adnectin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General</masterLabel>
            <translation><!-- IMS General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IXEMPRA® (ixabepilone)</masterLabel>
            <translation><!-- IXEMPRA® (ixabepilone) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>JAK2 Inhibitor</masterLabel>
            <translation><!-- JAK2 Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release)</masterLabel>
            <translation><!-- KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>LPA1 Antagonist</masterLabel>
            <translation><!-- LPA1 Antagonist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>LXR Modulators</masterLabel>
            <translation><!-- LXR Modulators --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Mature Brands General</masterLabel>
            <translation><!-- Mature Brands General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Microtubule Stabilizer</masterLabel>
            <translation><!-- Microtubule Stabilizer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NRT Inhibitor</masterLabel>
            <translation><!-- NRT Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS General</masterLabel>
            <translation><!-- NS General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS5A Second Generation</masterLabel>
            <translation><!-- NS5A Second Generation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS5B Inhibitor</masterLabel>
            <translation><!-- NS5B Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS5B Primer Grip Inhibitor</masterLabel>
            <translation><!-- NS5B Primer Grip Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS5B Site 1 Inhibitor</masterLabel>
            <translation><!-- NS5B Site 1 Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX® (belatacept)</masterLabel>
            <translation><!-- NULOJIX® (belatacept) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Necitumumab</masterLabel>
            <translation><!-- Necitumumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Notch Inhibitors</masterLabel>
            <translation><!-- Notch Inhibitors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONGLYZA® (saxagliptin)</masterLabel>
            <translation><!-- ONGLYZA® (saxagliptin) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ORENCIA® (abatacept)</masterLabel>
            <translation><!-- ORENCIA® (abatacept) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Oncology General</masterLabel>
            <translation><!-- Oncology General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PCSK9 Adnectin</masterLabel>
            <translation><!-- PCSK9 Adnectin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PEG-FGF21</masterLabel>
            <translation><!-- PEG-FGF21 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PLAVIX® (clopidogrel bisulfate)</masterLabel>
            <translation><!-- PLAVIX® (clopidogrel bisulfate) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PRAVACHOL® (pravastatin sodium)</masterLabel>
            <translation><!-- PRAVACHOL® (pravastatin sodium) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Pegdinetanib (VEGF R-2 Adnectin)</masterLabel>
            <translation><!-- Pegdinetanib (VEGF R-2 Adnectin) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Peginterferon lambda-1a</masterLabel>
            <translation><!-- Peginterferon lambda-1a --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RECOTHROM® Thrombin, topical (recombinant)</masterLabel>
            <translation><!-- RECOTHROM® Thrombin, topical (recombinant) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>REYATAZ® (atazanavir sulfate)</masterLabel>
            <translation><!-- REYATAZ® (atazanavir sulfate) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SMO Antagonist</masterLabel>
            <translation><!-- SMO Antagonist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL® (dasatinib)</masterLabel>
            <translation><!-- SPRYCEL® (dasatinib) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SUSTIVA® (efavirenz)</masterLabel>
            <translation><!-- SUSTIVA® (efavirenz) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TAXOL® (paclitaxel)</masterLabel>
            <translation><!-- TAXOL® (paclitaxel) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TGR5 agonist</masterLabel>
            <translation><!-- TGR5 agonist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Tempra IV® (paracetamol)</masterLabel>
            <translation><!-- Tempra IV® (paracetamol) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Triple Reuptake Inhibitors</masterLabel>
            <translation><!-- Triple Reuptake Inhibitors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Urelumab (Anti-CD137)</masterLabel>
            <translation><!-- Urelumab (Anti-CD137) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VIDEX® (didanosine)</masterLabel>
            <translation><!-- VIDEX® (didanosine) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY™ (ipilimumab)</masterLabel>
            <translation><!-- YERVOY™ (ipilimumab) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>α-7 Nicotinic Agonist</masterLabel>
            <translation><!-- α-7 Nicotinic Agonist --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label>Sunum</label>
        <name>Presentation__c</name>
        <picklistValues>
            <masterLabel>CHS Diabetic Presentation</masterLabel>
            <translation>CHS Diyabetik Sunumu</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CHS Presentation</masterLabel>
            <translation>CHS Sunumu</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CR Presentation</masterLabel>
            <translation>CR Sunumu</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CR Presentation Diabetic Patients</masterLabel>
            <translation>CR Sunumu Diyabet Hastaları</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RLS Presentation</masterLabel>
            <translation>RLS Sunumu</translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Product Knowledge --></label>
        <name>Product_Knowledge_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>1 - Significant Gaps of Product Profile</masterLabel>
            <translation><!-- 1 - Significant Gaps of Product Profile --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>2 - Unable to comm general Med attributes</masterLabel>
            <translation><!-- 2 - Unable to comm general Med attributes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>3 - Significant gaps in TA Knowledge</masterLabel>
            <translation><!-- 3 - Significant gaps in TA Knowledge --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>4 - Variable knowledge of TA on diff topics</masterLabel>
            <translation><!-- 4 - Variable knowledge of TA on diff topics --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5 - Some misunderstandings of Product</masterLabel>
            <translation><!-- 5 - Some misunderstandings of Product --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>6 - Minor Gaps in BMS Product Knowledge</masterLabel>
            <translation><!-- 6 - Minor Gaps in BMS Product Knowledge --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>7 - High level of general TA Knowledge</masterLabel>
            <translation><!-- 7 - High level of general TA Knowledge --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>8 - Ability to accurately comm Product</masterLabel>
            <translation><!-- 8 - Ability to accurately comm Product --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>9 - Detailed Product knowledge</masterLabel>
            <translation><!-- 9 - Detailed Product knowledge --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Product Presentation: Proactive Deck --></label>
        <name>Product_Presentation_Proactive_Deck_BMS__c</name>
        <relationshipLabel><!-- Interaction Discussions --></relationshipLabel>
    </fields>
    <fields>
        <label>Ürün Stratejisi</label>
        <name>Product_Strategy_vod__c</name>
        <relationshipLabel>Ziyaret Müzakereleri</relationshipLabel>
    </fields>
    <fields>
        <label>Ürün Taktiği</label>
        <name>Product_Tactic_vod__c</name>
        <relationshipLabel>Ziyaret Müzakereleri</relationshipLabel>
    </fields>
    <fields>
        <label>Ürün</label>
        <name>Product_vod__c</name>
        <relationshipLabel>Ziyaret Müzakereleri</relationshipLabel>
    </fields>
    <fields>
        <label>Önerilen Segment</label>
        <name>Proposed_Segment_BMS_EMEA__c</name>
        <picklistValues>
            <masterLabel>BARACLUDE Proposed Segment A</masterLabel>
            <translation><!-- BARACLUDE Proposed Segment A --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Believers</masterLabel>
            <translation>Ürüne İnananlar</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Cautious Experimenters</masterLabel>
            <translation>Tedbirli Deneyen</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Consider all PD1 the same</masterLabel>
            <translation><!-- Consider all PD1 the same --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Disengaged Traditionalist</masterLabel>
            <translation>Gelenekselci</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Early Line User</masterLabel>
            <translation>Erken Basamakta Tercih Edenler</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Fast, broad adoption of DAAs</masterLabel>
            <translation>Segment A-Geniş kullanım</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glivec First</masterLabel>
            <translation>İlk Seçenek Glivec</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Growing Use in 1st bio switch</masterLabel>
            <translation>İlk Switch Tercihini Arttıran</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Holistic Sprycel users</masterLabel>
            <translation>Sprycel Tercih Edenler</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Late line user</masterLabel>
            <translation>Geç Basamakta Tercih Edenler</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Low or No IV Capacity</masterLabel>
            <translation>IV Tercihi Düşük veya Yok</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lower, conservative use of DAAs</masterLabel>
            <translation>Segment C-GT3 ile ilgileniyor</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>More cautious adoption of DAAs</masterLabel>
            <translation>Segment B-GT3 üzerine taahhüt</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No interest/No use</masterLabel>
            <translation>Segmenti, İlgisi ve kullanımı yok</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prefers BRAF/MEK Inhibitors 1st line</masterLabel>
            <translation><!-- Prefers BRAF/MEK Inhibitors 1st line --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prefers Keytruda</masterLabel>
            <translation><!-- Prefers Keytruda --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prefers Opdivo</masterLabel>
            <translation><!-- Prefers Opdivo --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prefers Yervoy 1st line</masterLabel>
            <translation><!-- Prefers Yervoy 1st line --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Simple Decisions</masterLabel>
            <translation>Hızlı Karar Veren</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Tasigna Belivers</masterLabel>
            <translation>Tasigna Tercih Edenler</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unconvienced Followers</masterLabel>
            <translation>Referans Takip Edenler</translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Question --></label>
        <name>Question_BMS__c</name>
    </fields>
    <fields>
        <label>Kısıtlanmış Yorumlar</label>
        <name>Restricted_Comments__c</name>
    </fields>
    <fields>
        <label>Slaytlar</label>
        <name>Slides__c</name>
    </fields>
    <fields>
        <label><!-- Source --></label>
        <name>Source_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Speaker Training: Proactive Deck --></label>
        <name>Speaker_Training_Proactive_Deck_BMS__c</name>
        <relationshipLabel><!-- Interaction Discussions --></relationshipLabel>
    </fields>
    <fields>
        <label>Kullanıcı</label>
        <name>User_vod__c</name>
        <relationshipLabel>Ziyaret Müzakereleri</relationshipLabel>
    </fields>
    <fields>
        <label><!-- Webcast ID --></label>
        <name>Webcast_ID_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Y --></label>
        <name>Y_BMS__c</name>
    </fields>
    <fields>
        <label><!-- iPlan Deck Name --></label>
        <name>iPlan_Deck_Name_BMS__c</name>
    </fields>
    <fields>
        <label><!-- iPlan Product ID --></label>
        <name>iPlan_Product_ID_BMS__c</name>
    </fields>
    <fields>
        <label><!-- iPlan Product Name --></label>
        <name>iPlan_Product_Name_BMS__c</name>
    </fields>
    <fields>
        <label><!-- iPlan Status --></label>
        <name>iPlan_Status_BMS__c</name>
        <picklistValues>
            <masterLabel>Invalid CMEH ID</masterLabel>
            <translation><!-- Invalid CMEH ID --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Invalid Slide Deck ID</masterLabel>
            <translation><!-- Invalid Slide Deck ID --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Success</masterLabel>
            <translation><!-- Success --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label>Ürün</label>
        <name>zvod_Product_Map_vod__c</name>
        <picklistValues>
            <masterLabel>ABATACEPT</masterLabel>
            <translation><!-- ABATACEPT --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>APIXABAN</masterLabel>
            <translation><!-- APIXABAN --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ATAZANAVIR</masterLabel>
            <translation><!-- ATAZANAVIR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ATRIAL FIBRILLATION (APIXABAN)</masterLabel>
            <translation><!-- ATRIAL FIBRILLATION (APIXABAN) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BARACLUDE</masterLabel>
            <translation><!-- BARACLUDE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BELATACEPT</masterLabel>
            <translation><!-- BELATACEPT --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BIOMARKERS (ONCOLOGY)</masterLabel>
            <translation><!-- BIOMARKERS (ONCOLOGY) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BLADDER (NIVOLUMAB)</masterLabel>
            <translation><!-- BLADDER (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-663068-03</masterLabel>
            <translation><!-- BMS-663068-03 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-931699-01</masterLabel>
            <translation><!-- BMS-931699-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986001</masterLabel>
            <translation><!-- BMS-986001 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986001-01</masterLabel>
            <translation><!-- BMS-986001-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986004-01</masterLabel>
            <translation><!-- BMS-986004-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986090-01</masterLabel>
            <translation><!-- BMS-986090-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986104-01</masterLabel>
            <translation><!-- BMS-986104-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986142-01</masterLabel>
            <translation><!-- BMS-986142-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986165-01</masterLabel>
            <translation><!-- BMS-986165-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986166-02</masterLabel>
            <translation><!-- BMS-986166-02 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986184-01</masterLabel>
            <translation><!-- BMS-986184-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986195-01</masterLabel>
            <translation><!-- BMS-986195-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986202-01</masterLabel>
            <translation><!-- BMS-986202-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BRIVANIB</masterLabel>
            <translation><!-- BRIVANIB --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BYDUREON</masterLabel>
            <translation><!-- BYDUREON --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BYETTA</masterLabel>
            <translation><!-- BYETTA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CARDIOVASCULAR</masterLabel>
            <translation><!-- CARDIOVASCULAR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CHRONIC MYLOID LEUKEMIA/ACUTE LYMPHOCYTIC LEUKEMIA (DASATINIB)</masterLabel>
            <translation><!-- CHRONIC MYLOID LEUKEMIA/ACUTE LYMPHOCYTIC LEUKEMIA (DASATINIB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>COLORECTAL (NIVOLUMAB)</masterLabel>
            <translation><!-- COLORECTAL (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DACLATASVIR DIHYDROCHLORIDE</masterLabel>
            <translation><!-- DACLATASVIR DIHYDROCHLORIDE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DAKLINZA</masterLabel>
            <translation><!-- DAKLINZA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DAPAGLIFLOZIN</masterLabel>
            <translation><!-- DAPAGLIFLOZIN --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DASATINIB</masterLabel>
            <translation><!-- DASATINIB --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DELETE</masterLabel>
            <translation>SİL</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EFAVIRENZ</masterLabel>
            <translation><!-- EFAVIRENZ --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ELIQUIS</masterLabel>
            <translation><!-- ELIQUIS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ELOTUZUMAB</masterLabel>
            <translation><!-- ELOTUZUMAB --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EMPLICITI</masterLabel>
            <translation><!-- EMPLICITI --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ENTECAVIR</masterLabel>
            <translation><!-- ENTECAVIR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EXENATIDE</masterLabel>
            <translation><!-- EXENATIDE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GASTRIC (NIVOLUMAB)</masterLabel>
            <translation><!-- GASTRIC (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GLIOBLASTOMA (NIVOLUMAB)</masterLabel>
            <translation><!-- GLIOBLASTOMA (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HBV</masterLabel>
            <translation><!-- HBV --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCC (NIVOLUMAB)</masterLabel>
            <translation><!-- HCC (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCV</masterLabel>
            <translation><!-- HCV --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCV Portfolio</masterLabel>
            <translation><!-- HCV Portfolio --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HEAD AND NECK (NIVOLUMAB)</masterLabel>
            <translation><!-- HEAD AND NECK (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HEMATOLOGY</masterLabel>
            <translation><!-- HEMATOLOGY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HEPATITIS (ENTECAVIR/HCV PORTFOLIO)</masterLabel>
            <translation><!-- HEPATITIS (ENTECAVIR/HCV PORTFOLIO) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV (ATAZANAVIR/EFAVIRENZ)</masterLabel>
            <translation><!-- HIV (ATAZANAVIR/EFAVIRENZ) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV NRTI BMS-986001</masterLabel>
            <translation><!-- HIV NRTI BMS-986001 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV attachment inhibitor BMS-663068</masterLabel>
            <translation><!-- HIV attachment inhibitor BMS-663068 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMMUNO-ONCOLOGY</masterLabel>
            <translation><!-- IMMUNO-ONCOLOGY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMMUNOLOGY</masterLabel>
            <translation><!-- IMMUNOLOGY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IPILIMUMAB</masterLabel>
            <translation><!-- IPILIMUMAB --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>KOMBOGLYZE</masterLabel>
            <translation><!-- KOMBOGLYZE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>LUNG (IPILIMUMAB/NIVOLUMAB)</masterLabel>
            <translation><!-- LUNG (IPILIMUMAB/NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>LUNG (NIVOLUMAB)</masterLabel>
            <translation><!-- LUNG (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>LYMPHOMA (NIVOLUMAB)</masterLabel>
            <translation><!-- LYMPHOMA (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MELANOMA</masterLabel>
            <translation><!-- MELANOMA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MELANOMA (IPILIMUMAB)</masterLabel>
            <translation><!-- MELANOMA (IPILIMUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MELANOMA (IPILIMUMAB/NIVOLUMAB)</masterLabel>
            <translation><!-- MELANOMA (IPILIMUMAB/NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MELANOMA (NIVOLUMAB)</masterLabel>
            <translation><!-- MELANOMA (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MULTIPLE MYELOMA (ELOTUZUMAB)</masterLabel>
            <translation><!-- MULTIPLE MYELOMA (ELOTUZUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NIVOLUMAB</masterLabel>
            <translation><!-- NIVOLUMAB --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NIVOLUMAB BMS</masterLabel>
            <translation><!-- NIVOLUMAB BMS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NIVOLUMAB BMS LUNG</masterLabel>
            <translation><!-- NIVOLUMAB BMS LUNG --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NON-BRANDED ACTIVITY</masterLabel>
            <translation><!-- NON-BRANDED ACTIVITY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>OESOPHAGEAL (NIVOLUMAB)</masterLabel>
            <translation><!-- OESOPHAGEAL (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONCOLOGY</masterLabel>
            <translation><!-- ONCOLOGY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONGLYZA</masterLabel>
            <translation><!-- ONGLYZA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>OPDIVO</masterLabel>
            <translation><!-- OPDIVO --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>OPDIVO LUNG</masterLabel>
            <translation><!-- OPDIVO LUNG --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>OPDIVO MELANOMA</masterLabel>
            <translation><!-- OPDIVO MELANOMA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>OPDIVO RCC</masterLabel>
            <translation><!-- OPDIVO RCC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ORENCIA</masterLabel>
            <translation><!-- ORENCIA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PANCREATIC (NIVOLUMAB)</masterLabel>
            <translation><!-- PANCREATIC (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PROSTATE (NIVOLUMAB)</masterLabel>
            <translation><!-- PROSTATE (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>REGIMEN (OPDIVO + YERVOY) MELANOMA</masterLabel>
            <translation><!-- REGIMEN (OPDIVO + YERVOY) MELANOMA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RENAL (NIVOLUMAB)</masterLabel>
            <translation><!-- RENAL (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>REYATAZ</masterLabel>
            <translation><!-- REYATAZ --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RHEUMATOID ARTHRITIS (ABATACEPT)</masterLabel>
            <translation><!-- RHEUMATOID ARTHRITIS (ABATACEPT) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SAXAGLITPTIN</masterLabel>
            <translation><!-- SAXAGLITPTIN --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL</masterLabel>
            <translation><!-- SPRYCEL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TRANSPLANT (BELATACEPT)</masterLabel>
            <translation><!-- TRANSPLANT (BELATACEPT) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ULOCUPLUMAB</masterLabel>
            <translation><!-- ULOCUPLUMAB --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>URELUMAB</masterLabel>
            <translation><!-- URELUMAB --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VENOUS THROMBOEMBOLISM (APIXABAN)</masterLabel>
            <translation><!-- VENOUS THROMBOEMBOLISM (APIXABAN) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VIROLOGY</masterLabel>
            <translation><!-- VIROLOGY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY</masterLabel>
            <translation><!-- YERVOY --></translation>
        </picklistValues>
    </fields>
    <nameFieldLabel><!-- Interaction Discussion --></nameFieldLabel>
    <recordTypes>
        <label><!-- BMS - CAN - KAM Interaction --></label>
        <name>BMS_CAN_KAM_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - CAN - MSL Interaction --></label>
        <name>BMS_CAN_MSL_Interaction_BMS_CANADA</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - CAN - Sales Rep Interaction --></label>
        <name>BMS_CAN_Sales_Rep_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - CHINA MSL Interaction --></label>
        <name>BMS_CHINA_MSL_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - CHINA SALES Interaction --></label>
        <name>BMS_CHINA_SALES_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - CHINA Sales Interaction (1Group Call) --></label>
        <name>BMS_CHINA_Sales_Interaction_Group_Call</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - CHINA Sales Interaction (Others) --></label>
        <name>BMS_CHINA_Sales_Interaction_Others</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - CHINA Sales Interaction (2Reminder Call) --></label>
        <name>BMS_CHINA_Sales_Interaction_Reminder_Call</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - CHINA Sales Interaction (3Social Call) --></label>
        <name>BMS_CHINA_Sales_Interaction_Social_Call</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - EMEA - EPM Interaction --></label>
        <name>BMS_EMEA_EPM_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label>BMS - EMEA - Merkez Ofis Etkileşimi</label>
        <name>BMS_EMEA_HQ_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label>BMS - EMEA MSL Etkileşimi</label>
        <name>BMS_EMEA_MSL_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label>BMS - EMEA Satış Temsilcisi Etkileşimi</label>
        <name>BMS_EMEA_Sales_Rep_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - MEA MSL Interaction --></label>
        <name>BMS_MEA_MSL_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - MEA Sales Rep Interaction --></label>
        <name>BMS_MEA_Sales_Rep_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - MSL Interaction --></label>
        <name>BMS_MSL_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - Non-Branded Interaction --></label>
        <name>BMS_Non_Branded_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label>Ziyaret Raporu</label>
        <name>CallReport_vod</name>
    </recordTypes>
    <recordTypes>
        <label>Etkinlik_vod</label>
        <name>Event_vod</name>
    </recordTypes>
    <recordTypes>
        <label>MSL Toplantısı Hakkında Kısa Bilgi</label>
        <name>MSLMeetingBrief_vod</name>
    </recordTypes>
    <recordTypes>
        <label>Toplantı Hakkında Kısa Bilgi</label>
        <name>MeetingBrief_vod</name>
    </recordTypes>
    <validationRules>
        <errorMessage><!-- A Clinical Trial must be selected when Topic is CT and must be left empty otherwise. --></errorMessage>
        <name>BMS_EMEA_CTrequiredForMSMScenarios</name>
    </validationRules>
    <validationRules>
        <errorMessage><!-- Engagement Activity : Account should be the same the Interaction: Account --></errorMessage>
        <name>BMS_EMEA_EA_Account_Match_On_Interaction</name>
    </validationRules>
    <validationRules>
        <errorMessage><!-- A Medical Communication Topic must be selected when Topic is MCT and must be left empty otherwise. --></errorMessage>
        <name>BMS_EMEA_MCTrequiredForMSMScenarios</name>
    </validationRules>
</CustomObjectTranslation>
